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ABSTRACT
Layered double hydroxides (LDH) comprise a class of materials that can be either found
as natural minerals or can be synthetically prepared. Their structure is composed of a
mixture of divalent and trivalent metal cations, forming brucite-like layers, that are
neutralized with anions in the interlayer gallery. They have unique physical and chemical
characteristics such as: high surface area, large charge density, biocompatibility and
exchange capacity. These have attracted attention to the LDHs as potential drug delivery
vehicles.
Graphene (G) has also attracted the attention to exceptional properties, such as huge
surface area, charge density concentration, membrane permeability by piercing
mechanism and many others, expanding its use to include biomedical applications, such
as drug delivery. Moreover, the possibility of large scale production of exfoliated
graphene oxide (GO) sheets from G offered a further opportunity for their use. GO has a
high exposed oxygenated surface that allows loading of large number of drugs by
different bonding interactions and is dispersible in water.
Alendronate sodium is a water soluble nitrogen containing bisphosphonate (nBP) drug,
that has low bioavailabilty (< 1 %) due to its low epithelial permeability. It also exhibits
gastrointestinal adverse effects.
The objective of the work is to create a hybrid nanocomposite of Zn-Al LDH in its nitrate
form with G/GO, (G/GO-Zn-Al-NO3 LDH), combining the properties of these structures:
membrane permeability and large interacting surface of G or GO, the buffering effect and
the capability of the LDH in storing and controlling the drug release. The hybrid
nanocomposites incorporated 2% w/w of G or GO with two different M2+/M3+ ratios of
LDH, 2:1 and 3:1. They were loaded with the drug by co-precipitation and ion exchange.
The samples were characterized by XRD, FTIR, Zetasizer analyzer, and the amount of
drug loaded and released were determined by UV/Vis spectroscopy, and the results were
compared to those of drug-LDH controls. Samples that have show successful
intercalation of the drug in bi-layered arrangement are: co-precipitation samples using
M2+/M3+ ratio of 3:1 (drug-LDH, G/GO-LDH), and ion-exchange samples, that don’t
incorporate G/GO (drug-LDH), prepared using either M2+/M3+ ratios of 2:1or 3:1. Their
loading amounts ranged from 25.4 to 51 % w/w, and they exhibited a sustained release
over 24 hours with a release percentages, ranging from 2.1% (1.07 mg) up to 4.2 % (1.52
mg). The other samples showed loading by surface adsorption on brucite-like layers of
the LDH and the G or GO. They have drug loading amounts ranging, from 12.4 to 57.3 %
w/w. This work demonstrated the potential of G/GO-Zn-Al LDH nanocomposites for
sustained drug delivery.
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Chapter 1.
Introduction

1

1. Introduction
1.1

Layered double hydroxides

Layered double hydroxides (LDH) comprise a class of materials that can be either found
as natural minerals in the soil, in sediments, as precipitants of saline water and hazardous
waste sites, or could be synthetically prepared. They are used in a wide range of
applications such as catalysis, filtration, drug or gene delivery, as exchangeable or
absorbent materials, additives in polymer matrices or to create composites with other
nanomaterials. These applications are based on the unique physical and chemical
characteristics that LDHs possess such as high surface area, stability, large charge
density, inertness, buffering effect, biocompatibility and great exchangeable capacity, in
addition to the flexibility of controlling the surface layers and interlayer gallery content
[1][2][3][4][5].

1.1.1. Structure of LDH:
LDHs are also known as mixed-metal-hydroxide anionic clays or hydrotalcite-like
materials. Their structure is based on that of brucite [
], which consists of
Magnesium ions that are octahedrally surrounded by hydroxide ions. The octahedral units
are connected end to end to form infinite layers and then these layers stack over each
other to give a three dimensional structure. When a fraction of the divalent metal cations
is substituted with trivalent cations, the hydroxide layers become positively charged.
These positive layers are charge-balanced by the intercalation of anions in the interlayer
gallery, which also contains water molecules, giving rise to Hydrotalcite, figure (1-1).
Hydrotalcite was the first LDH discovered; it was introduced by Manasse in 1915, having
a chemical formula of [
]
.
], and has been used as the reference
term. After which Feitknecht in the late 1930s and 1940s introduced the term (Double
sheet structure), describing a structure with intercalated hydroxide layers. And after the
use of X-Ray diffraction for the study of minerals in the 1960’s, Allman and Taylor had
well understood the exact structure of LDH [1][3][5][6].
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Fig 1-1. Schematic representation of hydrotalcite three dimensional structure [3].

Different compositions of LDH materials are prepared by changing the type of divalent
and trivalent cations as well as the interlayer anions, but still maintaining a general
formula of
.m O, where
and
are the divalent
and trivalent metal cations in the hydroxide layers respectively. Pure LDH structures exist
at values of x in the range of 0.2 < < 0.33, where x represents the metal ratio as
/
(
+
) or in the range of 2-4 when expressed as
/
ratio. When the value
is higher than 0.33, an impure form of LDH is formed due to repulsion between the
increased positive charge density of the trivalent metal ions, allowing the inclusion of
foreign ions. For values less than 0.2, the lower positive charge density allows for less
anionic inclusion, which would prevent the formation of the metal hydroxide and the
structure collapses [1][3][6].
There are a wide variety of divalent and trivalent metal cations to choose from, with
different ionic radii as shown in table (1-1) [3]. The metals are chosen according to the
proper ionic radius that can form the hydroxide layers, therefore the most preferential
radii are the ones close to those of Mg2+and Al3+ ions as in brucite for divalent and
trivalent metal cations respectively [1]. The order of stability is Mg < Mn < Co ≈ Ni < Zn
for divalent metal cations, and Al < Fe for trivalent metal cations [1].

3

Table 1-1. Ionic radii of some common divalent and trivalent metal cations [3].

M2+

Radius
(nm)

M3+

Radius
(nm)

Fe
Co
Ni
Mg
Cu
Zn
Mn
Pd
Ti
Cd
Ca

0.061
0.065
0.069
0.072
0.073
0.074
0.083
0.086
0.086
0.095
0.100

Al
Co
Fe
Mn
Ga
Rh
Ru
Cr
V
In
Y
La

0.054
0.055
0.055
0.058
0.062
0.067
0.068
0.069
0.074
0.080
0.090
0.103

V4+
Ti4+
Sn4+
Zr4+

0.058
0.061
0.069
0.072

Li+
Na+

0.076
0.102

While
is the interlayer exchangeable anions, there is no limitation to the type of
anions that could be incorporated within the interlayer galleries, as long as they
compensate the positive charges of the hydroxide layers and generate purely prepared
LDHs. Precautions are needed during preparation if using anions other than carbonates to
prevent contamination with carbon dioxide from the aqueous solution or the surrounding
environment. However, anions have different structures, radii (table 2-1), charges and
charge densities that affect the basal spacing (interlayer distance + thickness of one
brucite-like layer) or height of the LDH [3][6]. The charge density and bond strength are
arranged in the following order:
<
[3].
The weaker bonded anions could be easily exchangeable with other strongly bonded
anions that are favored to be taken by the positively charged hydroxide layers, this
characteristic provides the LDHs with their exchange capacity property. Finally m is the
number of water molecules in the interlayer gallery filling the unoccupied spaces made
by the anions [1][2][3].
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Table 1-2. Basal spacing values given by different intercalated anions in LDH [6].

Anions

C’(A˚)

OH-

7.55

(CO3)2-

7.65

F-

7.66

Cl-

7.86

Br-

7.95

I-

8.16

(NO3)-

8.79

)2-

8.58

(ClO4)-

9.20

(SO4

1.1.2. Preparation of LDH:
Several synthetic techniques have been successfully used for the preparation of LDHs,
and these include co-precipitation, classical ion- exchange and reconstruction techniques,
with co-precipitation being the most simple, direct and commonly used among all
techniques. There are other techniques such as sol-gel, salt oxide, hydrothermal and
template methods and many others, but LDHs are not easily obtainable with these
techniques and therefore not frequently used [3][4].
A- Co-precipitation
In this preparation method, the synthesis conditions should reach supersaturation for the
metal cations to precipitate, which takes place by controlling the pH at a value higher
than or equal to the value at which the most soluble hydroxide is precipitated. Table (3-1)
shows the pH values at which some metal cations reach supersaturation to create the
hydroxide layers. The co-precipitation reaction could take place either at low
supersaturation or high supersaturation conditions. In the former case, two solutions are
added simultaneously together, one containing a mixture of divalent and trivalent metal
salts with the ratio of choice and the other containing an alkali to maintain the desired pH,
all into an aqueous solution containing the desired interlayer anions, and the pH is
maintained by either manual control or by using an automated titration device. The anion
that is to be intercalated should be of higher affinity to LDH and in excess amount to
compete with the anions of the metal salts. Therefore, the most commonly used anions in
metal salt precursors are nitrates and chlorides due to their weak affinity for LDHs and
thus could be easily replaced with others. However, the desired anion could be readily
included in the metal salt precursors, and in this case the alkali is added directly into a
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solution of the metal salt precursors till the desired pH is reached. In case acarbonates are
not the intercalating anions, precautions are to be taken by carrying the reaction under a
nitrogen atmosphere, because of the high affinity of carbonates to LDHs. The advantages
of the low supersaturation technique, are the capability to control the charge density of
the hydroxide layers by controlling the pH, and the production of highly crystalline
LDHs, that is for the increased rate of crystal growth rather than the rate of nucleation
[1][3][4][6].
As for the case of high supersaturation, the mixed metal salt solution is added to an
alkaline solution containing the desired interlayer anion in excess. However, this
technique has some disadvantages such as the generation of less crystalline and impure
LDHs due to the increased rate of nucleation at the expense of crystal growth, because of
the continuous alteration in the solution’s pH [1][3][4][6].

Table 1-3. pH values of precipitation of some M3+ and M2+ hydroxides [1][6].

Cation

pH at 10-2 M

pH at 10-4 M

pH at which hydroxide
re-dissolves

Al3+

3.9

8

9.0-12

Cr3+

5.0

9.5

12.5

Cu2+

5.0

6.5

Zn2+

6.5

8.0

Ni2+

7

8.5

Fe2+

7.5

9.0

Co2+

7.5

9.0

Mn2+

8.5

10

14
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B- Ion exchange
The ion exchange is another frequently used method when the co-precipitation technique
is not applicable, such as when the divalent and trivalent metal cations or interlayer
anions are unstable in alkaline media, or when the desired anions are difficult to
intercalate by co-precipitation but rather favor direct anionic exchange. In this technique,
the weakly held anions with low affinity to LDHs are exchangeable by the desired anions
of higher affinity, depending mainly on the electrostatic interaction between the
positively charged hosting sheets and the exchanging anions [1][3].
The exchange takes place by stirring the LDH precursors with an excess of the desired
anion in a solution [1][3]. The exchange follows one of the two following schemes:
LDH.Am- + Xn-

LDH.(Xn-)m/n + Am-

scheme. 1

or
LDH.Am- + Xn- + mH+

LDH.(Xn- )m/n + HmA

scheme. 2

In the first scheme, the LDH precursors contain weakly bound anions such as nitrates,
chlorides or perchlorates that are easily exchangeable with the anions to be intercalated.
While the second scheme, which was firstly proposed by Bish, uses LDH precursors
containing anions liable to acidic attack, such as carbonates and carboxylates [1].
There are some factors that should be considered for a successful ionic exchange; first,
the affinity of the desired anion for the exchange, which increases with the increase of the
ionic charges and the decrease of the ionic radii. Secondly, the solution medium for the
exchange, the proper medium would allow the expansion of the LDH interlayer spacing
for the exchange to take place. The aqueous medium favors the exchange by inorganic
anions, while the organic medium favors the exchange by organic anions. The third factor
is the pH of the medium, the low pH favors the exchange of less acidic anions with other
more acidic anions from the solution, taking into consideration that at pH lower than 4
the LDH would begin to dissolve. And at last the effect of the divalent and trivalent metal
composition in the hydroxide layers expressed as M2+/ M3+ ratio, since it affect the
charge density of the sheets and the hydration state, and hence affect the exchange with
the incoming anions. Other factors such as temperature also has an influence on the
exchange, since temperature favors the exchange, but too high temperature would distort
the LDH structure [1][7].
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C- Reconstruction
Reconstruction is another common preparation technique, also referred to as
regeneration, restoration, rehydration, calcination-rehydration process or simply
“structural memory effect”. In this technique the LDH is heated at a high temperature
(calcined) to remove the interlayer anions, water molecules and hydroxyl groups,
resulting in a mixed metal oxide. The calcined product is then rehydrated with water to
regenerate the hydroxyl layers, and the interlayer anions and water molecules based on
the memory effect of LDH. During regeneration, the anion of desire in the rehydrating
water is incorporated into the interlayer gallery. The reconstruction process is greatly
influenced by the pre-calcination temperature. For calcinations at temperatures less than
or equal to 550 ºC, the reconstruction is complete within 24 hrs, while for calcinations at
750 ºC, reconstruction requires 3 days to be complete. At 1000 ºC only partial
reconstruction is observed. The advantages of this process is the ability to intercalate
large guests that are difficult to intercalate by co-precipitation or ion-exchange and it
ensures the absence of other competing anions such as the inorganic anions of metal salts.
However, reconstruction is more complicated than co-precipitaion and ion exchange and
produces less crystalline LDH [8].

1.1.3. Post treatment of prepared LDH samples:
The synthesized LDHs are usually of poor crystallinity with disordered metal hydroxide
layers. In the case of co-precipitation, the addition process of salt precursors and alkali is
long enough for simultaneous nucleation and aging to take place, resulting in wide size
distribution of crystals. Therefore, for an improved uniformity and crystallinity, the
prepared precipitate is thermally treated at a temperature range of 273-373 K for few
hours or days. The aging takes place via Ostwald ripening, by which large perfect
crystallites grow and smaller ones disappear in the solution. Additionally, the produced
precipitant should be washed thoroughly with deionized water to remove excess ions that
may continue to react with the formed LDH [1][3][6].

1.1.4. Precautions during LDH preparation:
As mentioned previously, LDHs have very high affinity for carbonate anions, and in case
it is not the desired anion, the reaction should take place under nitrogen to exclude
atmospheric carbon dioxide. Atmospheric oxygen should be excluded as well, in case the
metal cations in the hydroxide layers are liable to oxidation such as divalent manganese,
cobalt, iron and trivalent vanadium [1][3].
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1.1.5. Applications of LDH:
As mentioned previously, LDHs have been employed in various applications in present
and others expected in the future. Their properties can be easily tailored to fit the
specifications of any required application. These properties are relevant to their high
surface area, high exchange capacity; to intercalate various organic and inorganic guests,
high adsorption capacity, thermal stability and reconstruction at mild conditions via
“memory effect” [5][9].
LDHs are commonly known for their use in catalysis, in the form of precursors, supports,
or as actual catalysts. In addition to their use as adsorbents and exchange materials for
water treatment to capture organic and inorganic wastes, specially that they are thermally
stable and able to regenerate [10]. The chemical inertness, biocompatibility and null
toxicity of LDHs had increased their use in the biological field [2][5]. LDHs are very
excellent intracellular carriers, that can efficiently penetrate cell membranes and deliver
high amounts of biological molecules into the target cells [11]. They can be used to create
either a direct or sustained release dosage forms or as a storage compartments for drugs
that are unstable under the influence of sunlight and high temperature. They can protect
from gastric ulcers that are caused by some drugs such as anti-inflammatories, because of
their barrier property that are similar to that of gastric mucosa, and their acid buffering
effect. They enhance the water solubility of some non polar or slightly polar drugs,
increasing their bioavailability. LDHs are not limited to drug delivery, but include
negatively charged bio-molecules as well, such as single or double stranded DNA and
small nucleotide molecules to expand their use in gene therapy, biosensing or even
information storage in future approaches [5][9][10].
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1.2

Graphene

The first attempt to separate graphite layers was introduced by Boehm and co-workers in
1962 via chemical reduction of graphite oxide. In 2004, the thinnest layer unit of
graphite, namely graphene (G), was discovered by Geim and co-workers; they received a
Noble prize in physics for this discovery. Since then, thin layers of G have grabbed the
attention for their exceptional properties, including high electrical conductivity (
S/cm), extraordinary mechanical properties with Young’s modulus, Poisson’s ratio and
fracture strength of 1 TPa, 0.149 GPa and 130 GPa respectively, optical transparency,
thermal conductivity (5000 Wm-1 k-1), high carrier mobility at room temperature (250,000
cm2/V ) with charge carrier concentration of 1.4×1013 cm-2 and a huge surface area.
These discoveries lead to exploring various means to incorporate G in applications such
as in electronic and optoelectronic devices, as photoconductive materials in solar cells, in
medical imaging, drug delivery, tissue engineering and as nano-fillers to improve the
mechanical properties of some polymeric materials [11][12][13][15].

1.2.1. Structure of G:
G is a building unit for other carbon-based structures, it is rolled into spheres, cylinders or
stacked into layers to give fullerenes, nanotubes and graphite respectively
[13][14][15][16]. However, the flat sheets of G have outstood these carbon allotropes for
its unique properties and features [12].
G is a planar sheet of one-atom thickness (~ 0.33nm). It is composed of
-bonded
carbon atoms in two dimensional honeycomb Lattice. The unit cell of G lattice in real
space comprises two carbon atoms belonging to two different interpenetrated sub-lattices,
so that an atom from one sub-lattice is at the centre of the triangle defined by the other
sub-lattice with a carbon-carbon inter-atomic length of 0.142 nm. This arrangement
creates a triangular symmetry rather than a hexagonal one as shown in figure (1-2)
[11][12][14]. Each carbon atom in the lattice has three
-hybridized orbitals in the
same plane, providing the G sheets with its mechanical stability, while the unhybridized p
orbital is perpendicular to the molecular plane. The free delocalized π electrons of the
unhybridized p orbitals create a high electronic density above and below the 2D G plane,
providing it with a highly reactive surface that can immobilize a large number of
substances such as metals, drugs, bio-molecules, fluorescent probes and cells
[13][15][17].
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Fig 1-2. G layer consists of two interpenetrated triangular sub-lattice in two different colors, the atom of
one sub-lattice (A) is located at the centre of the triangle defined by the other sub-lattice (B) [15].

Although G’s unique properties are associated to its single plane sheet, it is difficult to
obtain G as a defect-free single layer due to its high surface area. This leads to the
formation of irreversible agglomerates or even the restacking of multiple layers via Van
der Waals interaction to form graphite again. Therefore, there are many chemical
attempts for graphite exfoliation that focus on intercalation, chemical derivatization,
thermal expansion, oxidation-reduction and use of surfactants, in order to maintain the
inherent properties of G, and to employ it in most of the proposed applications. These
chemical attempts produce a set of structures referred to as “G family nano-structures”,
that include bilayer and multilayer G, graphene oxide (GO) and reduced graphene oxide
(rGO), each one has its own surface chemistry, purity, defect density and compositions
[11][12][13][14][18].

1.2.2. Graphene oxide:
Surface functionalization of G sheets has been an efficient approach to prevent
graphene’s agglomeration by introducing small molecules in between layers. Graphene
oxide (GO) has been the most widely used form of exfoliated graphite [12][13]. It is a
highly oxidized form of G, prepared by strong oxidation of graphite followed by
sonication or other dispersion methods to provide monolayer materials, and can be further
modified chemically to obtain G-based materials with suitable properties for a specific
application [15][19][20].
As shown in figure (1-3), the surface of GO sheets is highly oxygenated bearing
epoxides, alcoholic groups, ketone carbonyls and carboxylic groups [15]. The carboxylate
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groups at the peripherals provide colloidal stability and pH-dependent negative surface
charges, while epoxide (˗O˗) and hydroxyl (˗OH) groups are present on the basal plane,
to allow for weak interactions such as hydrogen bonding and other surface reactions. The
basal plane also contains free π electrons from the unmodified G areas, which are
hydrophobic and can undergo π-π interactions. When the carbon atoms covalently bond
to these oxygen containing groups, they partially convert sp2 conjugated system to sp3,
weakening the van der Waals interactions between the sheets and increase the interlayer
spacing of graphite from 0.35 nm to 0.65 nm to be ready for further exfoliation to single
layers of GO. The oxidation and the harsh chemical treatments also impart topological
defects, vacancies, cracks and edges in G lattice, increasing the chemical reactivity of the
surface. The highly negative charged carboxylic and phenolic groups on the surface of
GO render it hydrophilic due to their ionization in water to form uniform dispersions,
which makes it very attractive for biological applications [13][14][15][18][21].

Fig 1-3. Structure of GO sheets [19].
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1.2.3. GO preparation:
The most common method used nowadays for the preparation of GO is the Hummers
method that was developed by Hummers and Offeman in 1958. The method is very
simple, fast and productive. It exposes graphite to strong oxidizing agents to introduce
oxygen containing functional groups on both sides of the single graphite sheets
[12][14][18][22][23].
A- Hummers method
The most suitable starting material is the expanded graphite flakes with an average
diameter of ~15 µm, because of its availability, cost effectiveness, and surface uniformity
to provide a better oxidation and exfoliation performance [18][23].
In this method, oxidation is achieved by adding concentrated sulfuric acid (H2SO4) into a
mixture of graphite flakes and NaNO3, all in an ice bath (0ºC). This is followed by the
addition of KMnO4 drop-wise to maintain the reaction temperature below 20ºC, and then
warmed to 35ºC. At this temperature range, distilled water is slowly added producing an
exotherm, and with the application of an external heat, temperature is maintained at 98ºC.
The reaction is then terminated with the addition of water and 30% H2O2. The final
mixture is purified by sifting, filtering and successive washing with distilled water, 30%
HCl and ethanol, with the repetition of sifting, filtration, centrifugation and decantation
after each wash. Finally it is dried under vacuum at room temperature for 24 hrs [18][24].
There are some disadvantages to the Hummers method, such as the release of toxic gases
like NO2 and N2O4, and the difficulty to remove the oxidation residues (i.e. Na+ and NO3) during purification. Moreover, it results in the production of GO with disrupted planes,
because H2SO4 /HNO3 mixtures act as chemical “scissors” and “drills” for the G planes to
facilitate the diffusion of the oxidants [18][22]. Hence, some modifications have been
introduced to create a more eco-friendly oxidation method, such as ‘modified Hummers’.
B- Modified Hummers method
In the improved method, 9:1 mixture of concentrated H2SO4 / H3PO4 is added to a
mixture of graphite and KMnO4, producing a slight exotherm of 35-40ºC. The NaNO3 is
excluded in this method, which is the source of the toxic gases produced in the classic
Hummers method, and is compensated for by increasing the amount of H2SO4 and
KMnO4. The KMnO4 is a very strong oxidizing agent in acidic media; therefore, it
improves the oxidation performance of H2SO4. The mixture is then heated to 50ºC and
stirred for 12 hours. After cooling to room temperature, the reaction is terminated by
pouring the mixture into ice containing 30% H2O2. Followed by purification with sifting,
filtration, centrifugation and decantation, and successive washing with distilled water,
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30% HCl and ethanol. For each wash, the mixture is sifted, filtered, centrifuged and
decanted then finally dried under vacuum at room temperature for 24 hours [18][22].
This improved method has some advantages over the unmodified Hummers, such as the
low cost and oxidation temperature, it is less exothermic and produces no toxic gases,
provides higher yield of GO with a less disrupted basal planes [18][24]. Therefore
modified Hummers method is the most preferred approach for graphite oxidation.
C- GO reduction
GO has some limitations with respect to its mechanical, electrical and thermal properties;
which are altered because of the functional groups that saturate the sp2 configuration.
These groups disrupt the electronic structure, rendering the GO electrically insulating and
reduce the charge-carrier concentration and mobility [12][13][14][21][25]. As for the
mechanical properties, the Young’s modulus is reduced to 0.15-0.35 TPa. In order to
restore these properties, GO undergoes reduction to decrease the oxygen content via
thermal, chemical or UV treatments in presence of hydrazine or other reducing agents
[13][18][21][25]. However, it will not be fully restored due to the additional defects, that
are introduced during the reduction process [17].

1.2.4. Applications of G and GO:
G has many unique properties that make it potentially promising in a large number of
applications. The possibility of large scale production of GO and reduced GO has
increased the opportunity for their use as reinforcements in polymer matrix composites.
That is for their special mechanical, chemical, electrical and barrier properties, and aspect
ratio [14][26][27]. These properties can contribute to exceptional features and high
performance of the composite, such as gas and moisture barrier properties,
electromagnetic shielding, electrical and thermal conductivity, increasing operating
temperature level and improving compression strength [12][27].
Nowadays, there is an increased attention towards solar cells that use G as an active
medium or as an electrode material, or taking the advantage of its chemical capabilities
for energy storage and generation. The revolutionary in the electronics field has also
utilized G as a planar channel material in high performance integrated circuits to produce
touch screens, light emitting diodes and others [26][27].
However, G has recently expanded its range of applications to include biomedical ones
such as in biosensors, tissue scaffolds, drug delivery, gene therapy or as antimicrobial
agent. Such applications are made possible because of its relative properties such as large
surface area, lateral dimensions, surface chemistry, purity and easy functionalization. It
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can be a very promising ultrasensitive electrochemical or biological sensor
[14][21][26][27]. Such sensing capability is made possible either via the charge transfer
between the G monolayer and the adsorbed molecules, which is eventually translated into
chemical responses, or via the functionalization of G with sensitive receptors for the
detection of wide range of biological molecules (e.g. glucose, DNA, cholesterol and
hemoglobin). In addition, it can serve as a single multi-dimensional measurement device.
Moreover, in tissue engineering, the G’s unique high elasticity and flexibility have been
very promising for its use as a reinforcement for biocompatible films, hydrogels and
other types of scaffolds [19][26][27][28].
As for drug delivery, GO disperses well in water and has a good stability in physiological
solutions, in addition to a large surface area, making it a good candidate as a drug
delivery vehicle that can be given for systematic targeting or local administration
[12][21][29]. Its large exposed surface area allows the high loading of a large number of
molecules ranging from small drug molecules to big molecules such as antibiotics, DNA,
proteins and genes with a good distribution and release profile. The hydrophobicity of G
and the untreated edges of GO have increased the loading options to include insoluble
drugs via π-π interactions and solving another challenge in drug delivery relevant to
membrane barrier penetration [19][21][27]. Since the work here focuses on the
biomedical applications, a great attention shall be given to its biological interactions,
biocompatibility and the limitations for its uses.

1.2.5. Biological interaction and toxicity of G and GO:

A- Biological interaction
The biomolecular interaction is responsible for the determination of cellular uptake, renal
clearance, blood-brain barrier permeability and other biological phenomena and
therefore, understanding the properties relevant to the interactions is important to control
G’s health and safety concerns [19][30].
The mechanisms by which graphene based materials (GBMs) interact with the cell’s lipid
bilayer, the layer that forms a barrier around all body cells, were introduced by Titov and
coworkers. They conducted coarse-grained molecular dynamic (CGMD) simulation on G
of different shapes, surface chemistries, different corners or edges, functionalizations and
hydrophilic/hydrophobic property, in order to illustrate the dynamic process of G
interaction with the lipid bilayer. In all cases the study agrees that G’s cellular uptake or
penetration takes place via spontaneous localized piercing of the membrane by the most
hydrophobic and sharpest edges of G, followed by spontaneous tilting of the G’s edges to
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maximize its interaction to include the whole surface to achieve full penetration into the
membrane interior as shown in figure (1-4). Therefore, the potential for G’s interaction to
the lipid bilayers is due to its extended two-dimensional surface (5-10µm),
hydrophobicity and sharp edges or protrusions, that are created during the fabrication and
exfoliation processes. Whereas, GO is partially hydrophobic with rough edges and
defects, that are produced during the harsh oxidation conditions, allowing it to interact as
well with the lipid bilayers [19][30][31].

Fig 1-4. Coarse-grained molecular dynamics simulations of interactions between a lipid bilayer, (A-D)
represent the small G sheet, and (E-H) represent interaction of larger multilayered G [30].

B- Toxicity
The effect of GBMs on living systems is very versatile and inconsistent, due to the
different fabrication techniques, sizes, shapes, surface charges and functional groups. All
of these properties need to be standardized in order to understand the exact mechanism of
GBMs toxicity and impact on human health. The effect of GBMs on living cells is
generally dependent on their concentration, exposure time and administration route.
GBMs given intravenously (I.V) and via inhalation are the most studied: they are found
to accumulate mainly in lung, liver and spleen, causing inflammation, pathological
changes and apoptosis to the cells [20][32][33][34]. The inflammation is assumed to be
due to the release of the reactive oxygen species (ROS) as a defense response against the
GBMs, that create a state of oxidative stress and damage the cells, but this mechanism is
still unclear. However, the effect is greatly dependent on the given dose: in case of large
doses equal or above 50 µg/ml they are found to show an obvious toxicity, while doses
below 20 µg/ml fail to show any toxicity [14][32][33]. Size also plays an important role
in evaluating the toxicity: sizes as small as 160± 90 nm induce high toxicity effects and
cell apoptosis at concentrations equal to 200 µg/ml, while large sizes of 780± 410 nm
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have less toxic effects causing only slight necrosis, respectively. As for medium sized
GBMs of 430± 300 nm neither apoptosis nor necrosis is induced except for a decrease in
cell viability at a dose of 200µg/ml. As for the studies made on GBMs that are
administered orally are very limited. One of these studies detects the presence of large
quantities of GBMs in the stomach and the intestines of mices within hours of ingestion,
which were undetectable after one week, indicating their fast fecal excretion [14][20].
Another recent study has investigated the presence of G in the form of GO and other
carbon nano-particles in the charred parts of roasted meat and in plant charcoal. This is
used to prepare an approved medicine for infants’ known as “grip water” to treat
stomachaches. Hardly any incidents of toxicity have been discovered [35].
Current studies on GBMs toxicity, as claimed by researchers, are so far acceptable, and
that the use of small doses may be safe. However, GBMs are more toxic in their free form
and their modifications are still essential [34]. These modifications are to improve
biocompatibility, solubility and reduce toxicity, and shall include all forms of G, even
GO which is the most water soluble and biocompatible amongst all [20][31]. They can be
modified with biocompatible, non-toxic materials either via covalent modifications such
as atom doping and molecular interactions that further disrupt G’s surface structure, or
non-covalent modifications such as Van der Waals, H-bonding or electrostatic
interactions which produce a more flexible structure without the alteration of their
surface strucrure [17][32]. Examples of successful modifications are poly ethylene glycol
(PEG) and dextran-functionalized G and GO that showed no significant toxicity or
apoptosis to mice cells via I.V injection at a dose of 20 mg/kg or oral intake of 100 mg/kg
of the mice’s weight [33] .
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1.3

Bisphosphonates

Bisphosphonates (BP) comprise a class of drugs that selectively prevent bone resorption
(i.e. bone mass loss), and treat a number of bone diseases, such as menopausal
osteoporosis, corticosteroid induced osteoporosis, Paget’s disease, malignant
hypercalcemia and metastasis, and other osteogenic imperfections [36][37].
They are analogues of the inorganic pyrophosphate: a cellular metabolic byproduct that
inhibits crystallization and prevents calcification in connective tissues, urinary tract and
other extracellular fluids via its strong binding affinity to mineral crystals. This activity
affects the minerals’ deposition inside the bone matrix and decreases its density.
Therefore, to maintain the mineralization balance and allow for crystal growth, this action
is reversed by alkaline phosphatase enzyme, which is present at the cellular linings; it
hydrolyses the pyrophosphate before entering the bone and affecting the bone matrix.
However, pyrophosphates do bind and promote the stabilization of formed crystals, and if
allowed to saturate in the bone matrix, they may increase the crystal deposits and the
bone density [38][39][40]. Therefore, non-hydrolyzable synthetic analogues such as the
BP, have been developed for therapeutic purpose. As shown in figure (1-5), the chemical
structure of BP comprises a carbon atom instead of oxygen which provides stability
against hydrolysis by alkaline phosphatase, and it also allows for the presence of two
more substituents/side groups than the phosphonate groups (R1 and R2). The binding
strength and potency of BP can be easily tailored by varying R1 and R2 side groups
respectively as shown in figure (1-6), which depicts their structure-activity relationship
[36][37][38].
BP are classified into three generations based on the group at R2 position. The first
generation lacks the nitrogen group such as clodronate and etidronate, the second
generation has a primary nitrogen group such as alendronate and ibandronate, while the
third generation contains a nitrogen group in a side chain cyclic ring as risedronate and
zoledronate [41]. The potency of BP has been improving with each generation and
nitrogen-containing bisphosphonates have proven to be the most potent generation and
with the highest binding affinity to bone cells [42].
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Inorganic pyrophosphate

Bisphosphonate

Figure 1-5. The chemical structure of inorganic pyrophosphate and BP [37].

When R1 is OH group.
Binding to hydroxyapatite is
enhanced.
P-C-P acts as a “ bone
hook” and is essential for
binging to hydroxyapatite.

The P-C-P group is
essential for biological
activity.
The R2 side chain
determines potency.

Figure 1-6. The structural-activity relationship of BP [36].

1.3.1. Nitrogen containing bisphosphonates:
As mentioned previously, the nitrogen containing bisphosphonates (nBP) are the most
potent, because the R2 side chain plays an important role in the interaction of BP to the
bone target and any slight change in the structure or conformation at R2 will dramatically
affect the potency [39]. The nBPs’ pharmacological effect is not only relevant to their
capability to bind and stabilize the mineral crystals, but also they interfere with relevant
metabolic pathways due to their structural similarities to active sites of some catalysts
such as squalene; a biomedical intermediate for the synthesis of plant and animal sterols
(ex. cholesterols). As shown in figure (1-7), they compete with squalene to interact with
the farensyl diphosphate synthase (FPP) in the mevalonate pathway. They therefore
inhibit the FPP induced isoprenylation (i.e. the addition of hydrophobic groups to
proteins to facilitate attachment to cell membranes) of some GTPase. This controls a
number of activities in the osteoclasts’ (bone cells that are responsible for resorbing bone
minerals). The inhibition of farensyl diphosphate synthase is dose-dependent: at low
19

concentrations, the mineral dissolution process is inhibited, at relatively high
concentrations osteoclast differentiation is inhibited, while at very high concentrations
osteoclast apoptosis (cell death) takes place [42][43].

nBPs
Geranylgeranyl-PP
Isoprenylation of GTPase

Fig 1-7. Pharmacological action of nBPs [42].

1.3.2. Biovailability of BP:
BP are administered either intravenously (I.V.) or orally. Although oral BP are more
convenient for patients than I.V., they have poor oral bioavailability (<1%) and cause
gastrointestinal adverse effects such as oesophagitis and diarrhea, which will need dose
adjustments to increase efficacy or lead to discontinuation because of incompliance. They
have low oral bioavailability because they are highly polar, negatively charged at
physiological pH of the intestine, which lead to unfavorable transport across the epithelial
barriers. Their absorption is also affected by food intake and calcium supplements, and
despite their high bioavailability at higher pH, they are taken after an overnight fast to
prevent food interference [36][41][44][45].
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1.3.3. Pharmacokinetics of BP:
The oral absorption of BP across the gastrointestinal tract takes place paracellularly (i.e.
passage of molecules between tight junction of the cells), because of their low transport
efficiency across the epithelial cells as mentioned previously. The absorbed dose is then
distributed equally between the bone from which the drug is slowly released and the
kidney for excretion. The amount of drug retained in the bone is partitioned between two
drug pools: one at the bone resting surface where the drug is mobilized during the bone
turnover into the bone fluid then into the blood, and the other partition is buried deep in
the bone matrix. The drug mobilized into the blood is recyclable again into the bone and
kidney till the amount is insufficient, while the drug embedded inside the bone remains
active until resorption is induced by the newly formed osteoclasts, and that is when an
additional dose has to be given to maintain the anti-resorptive efficacy. Although the
usual administered doses shows a plateau for the resoprtion suppression, a higher or more
frequent doses are recommended for higher efficiency [37][36][42].

1.3.4. Alendronate sodium:
Alendronate sodium [(4-amino-1-hydroxybutylidene)bisphosphonic acid Monosodium
Trihydrate] (figure 1-8), a water soluble nBP. It is the most efficient anti-resorptive agent
and potent farensyl diphosphate inhibitor to-date, and it is the drug of choice in the
treatment of hypercalcemia in malignancy cases, postmenopausal osteoporosis and many
other musculoskeletal disorders. Its clinical effect is based on increasing bone mineral
density and strength, and reducing risk of fracture. Its mechanism of action,
bioavailability and pharmacokinetics data are similar to the nBPs. It shows an oral
bioavailability averaged 0.75%, with a linear oral absorption increase from 5 to 80 mg
dose range. As a result of the addressed issues, many attempts have been made in order to
develop new formulations for the alendronate sodium to enhance its bioavailability
[37][45][46][47].
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Fig 1-8. The chemical structure of alendronate sodium in trihydrate form [37].

1.4. Statement of purpose
The aim of this research work is to prepare a new hybrid nanocomposite of G/GO-LDH,
and investigate its use as a drug delivery system for nitrogen containing bisphosphonate
(alendronate sodium), this entails:


Preparation of a hybrid nanocomposite of Zn-Al LDH in its nitrate form with
G/GO (G/GO-Zn-Al-NO3) using two different M2+/M3+ ratios of LDH (2:1 and
3:1).



Loading the hybrids with the alendronate sodium with two different techniques:
co-precipitation and ion-exchange.



Characterization of the samples by XRD, FTIR to determine successfully
intercalated samples, and mechanism of loading.



Determination of the loaded drug amounts and the study of the drug release from
the hybrids by UV spectroscopy.



Compare the performance of the hybrid nanocomposite samples with LDH
control with respect to drug loading and release.
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2. Literature Review
This chapter presents a review of the different approaches that have been developed to
improve the delivery of pharmaceutically active molecules, with emphasis on those based
on the utilization of LDH and GO as drug delivery platforms. A number of delivery
systems that were investigated for improving the unfavorable physiochemical properties
of alendronate sodium will also be represented.

2.1. LDH intercalated systems
2.1.1. Non Steroidal Anti-Inflammatory Drugs (NSAIDS) intercalated
LDHs:
NSAIDS anti-inflammatory drugs, are commonly used in cases of arthritic rheumatism,
osteoarthritis, muscle pain, metastatic bone pain, migraines and many other medical
cases. However, they are associated with low solubility, poor delivery control and
administration adverse effects; such as gastric and duodenal ulcers. Intercalation of
NSAIDS into the LDH matrix, has improved their water solubility and release rate. The
LDH has provided an additional advantage by introducing a buffering effect to protect
against the ulceration damages [48][49].
The anti-inflammatory fenbufen was intercalated by Evan et al. into Mg/Al and Li/Al
LDHs in their nitrate form by co-precipitation under pH 8 [50]. The drug was intercalated
successfully as monolayers in the LDH interlayer gallery, and upon increasing the pH
from 8 to 12, the amount of intercalated fenbufen was increased, indicating the possible
formation of bilayers as suggested by the increased gallery spacing. The Mg/Al LDH
system proved to be more effective as a controlled release system, giving a gradual
release over time compared to Li/Al LDH [48][50].
Del Arco et al. intercalated fenbufen into Mg/Al LDH and Mg/Al/Fe LDH systems, by
co-precipitation and ion exchange, using the chloride LDH form, and by reconstruction
using the LDH nitrate form [51]. The intercalation was successful in case of Mg/Al LDH
by the three preparation techniques, but fenbufen was only intercalated by coprecipitation and ion exchange in case of Mg/Al/Fe LDH. This was because Fe inhibited
the intercalation after the LDH reconstruction. The total drug release was more restrained
in case of the Mg/Al/Fe LDH system (only 59% in 1 h), due to the strong interaction
between the drug and the hydroxide layers, while the release from the Mg/Al system was
complete in only 2 h [48][51]. The study was extended by coating the LDH-drug hybrid
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with an enteric coat such as Eudragit® S100, and uniform and smooth microspheres were
produced, showing high stability at low pH (<7) [51]. The same results were found by
Evans et al., who proved that the strong interaction between the Eudragit® S100 and the
LDH further restrained the drug release [48].
Naproxen is another anti-inflammatory that was successfully intercalated by Duan et al.
into Mg/Al LDH in its nitrate form by ion exchange under pH 8. The study proved the
thermal stability of the system. This was acquired by the naproxen upon intercalation
compared to the free form, suggesting an additional advantage of the LDH as a promising
delivery system [48][52].
Berber et al. also intercalated the naproxen into Mg/Al LDH by co-precipitation and
reconstruction with the LDH chloride form at pH 8. The drug was intercalated more
successfully by co-precipitation than by reconstruction, and the drug dissolution in the
acidic media was improved compared to the free drug. The same approach was followed
by Del arco et al. using the three preparation techniques. The intercalated amount of
naproxen was almost the same in case of co-precipitation (44.2%) and ion exchange
(46.5%), but very low in case of reconstruction (38.4%) due to possible contamination
with interlayer carbonates. The drug dissolution was improved in acidic medium,
compared to the free drug and the release was found to be more controlled [48][53][54].
The Zn/Al LDH system was used by Hou and Jin to intercalate naproxen by the ion
exchange method [48][55]. The intercalation of the drug was successful, and the
interlayer distance increased to 18.78 Å, which is greater than the drug’s height (12.20
Å), indicating the arrangement of the drug as overlapped bilayers and high drug loading.
They studied the effect of some variables such as the structural charge density,
composition and the pH on the amount of the drug loaded, in addition to the effect of
using LDH on the drug release rate. The increase of the charge density increased the
amount of the drug loaded because of the interaction between the positively charged LDH
layers and the negatively charged naproxen. On the other hand, the increase of pH from 6
to 11 caused a linear decrease in the amount of loaded drug, because the charge density
decreased with the increase of pH [55]. The composition of the interlayer anions were
also of significance, both chlorides and carbonates were investigated as the interlayer
anions. It was found that the intercalation was more successful in the case of chlorides
because it was more readily exchanged with drug. Finally, the Zn/Al LDH was proved
efficienct as a controlled release system when compared to free naproxen [48][55].
Ambrogi et al. successfully intercalated the anti-inflammatory ibuprofen and diclofenac
in Mg/Al LDH with its chloride form by ion exchange, suggesting their arrangement as
monolayers and bilayers respectively, which was indicated by the increased value of the
interlayer space compared to the drugs’ molecules sizes. They investigated the LDH
25

capability to control the release of the drug. It was found that the release of ibuprofen and
diclofenac in the phosphate buffer solution took place over 24 hours, the slow release
being attributed to the rate of phosphate anions’ diffusion onto the interlayer gallery and
their exchange with the intercalated drug [48][56][57]. They extended their work to
prepare enteric-coated microparticles of diclofenac-LDH to protect against gastric attack.
The microparticles were prepared by an oil-in-oil solvent evaporation method, using the
intercalated LDH and a mixture of Eudragit® S100 and Eudragit® L100 polymers with a
ratio of 1:5 or 1:10 w/w. The microparticles combined between the two release strategies:
the pH-dependent polymer solubility and the ion exchange release mechanism of the
LDH [48][58].
Perioli et al. used the Zn/AL LDH with its bromide form to intercalate diclofenac drug,
using the ion exchange mechanism. After the successful intercalation, they studied the
effect of the particle size on the drug release [48][59]. The release of the drug from the
nano-sized and micro-sized particles were compared, showing no difference of their
release and indicating that the ion exchange was the rate-limiting step [59].
Rives et al. intercalated diclofenac and ketoprofen into Zn/Al and Mg/Al LDH systems
with its nitrate form by co-precipitation. The increased height of the interlayer gallery in
case of the two drugs is 23 Å, and when compared to the drugs’ molecular sizes,
suggested their arrangement as tilted bilayers. The strong interactions between the drug
and the LDH layers proved to be another indication to the thermal stability of the
intercalated drug at very high temperature compared to its free form [48][60].

2.1.2. GO and drug intercalated LDHs:
The first attempt for the use of GO/LDH hybrid in biological systems was reported by
Zhang et al. (2012). Their objective was to prepare antibiotic-intercalated LDH-GO
composite by a simple solvent evaporation method. The delivery system combined the
antibacterial activity of GO and its ability to incorporate a variety of drugs, and the
LDH’s ability to store the drug and control its release. A Mg-Al LDH, with nitrate as the
interlayer anion, was used as a precursor into which the benzyl penicillin (BP) antibiotic
was intercalated by ion exchange. The as-prepared BP-LDH was then mixed with GO
under vigorous shaking and ultra-sonication, relying on the formation of electrostatic
interactions between GO and LDH, followed by washing and drying completely. The
release of the drug from the hybrid was much slower than that of free LDH and could be
adjusted by controlling the GO/BP-LDH ratio: the lower the ratio of GO/BP-LDH the
higher the time of the release. As for the biological activity, the hybrid was observed to
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show a synergistic antibacterial effect, due to the combined antibacterial activity of the
BP and GO, which also increased with the decrease of the GO/BP-LDH [61].

2.2. GO based delivery systems
2.2.1. Delivery of anticancer drugs:
The use of chemotherapeutic drugs to treat cancer is challenged by their non-selective
cytotoxicity and hydrophobicity, which has imposed the need to develop efficient
targeted drug delivery systems [47]. GO serves as a promising drug delivery vehicle as its
high surface area is available for variable dynamic interactions with different biomolecules and drugs [62][63].
In 2008, Dai et al. pioneered the development of a modified GO for biological
applications. Six-armed polyethylene glycolamine polymer (PEG) was grafted onto the
surface of GO to impart biocompatibility and aqueous stability without aggregation. The
GO-PEG hybrid was then loaded with the anti-cancer doxorubicin (DOX) via π-π
stacking and hydrogen bonding at high loading capacity. The PEG shell gave the drug
high stability during blood circulation till it reached the tumor, where the drug was
released due to its increased solubility in acidic media [63][64].The tumor-targeting of
the GO-PEG-DOX system was based on the fact that the tumor microenvironment is
acidic (pH 5.5). On the other hand, PEG acts as a diffusion barrier that can adversely
delay the release of the drug. In 2012, Shi et al. solved this issue by developing a GO
delivery system with a redox-responsive detachable PEG shell. A cytamine modified
PEG (PEG-SS-NH2) was grafted onto the surface of GO via the disulphide linkage
(NGO-SS-mPEG) [65]. The encapsulated drug was rapidly released from the formulation
by selective degradation of the disulphide linkage when exposed to the relevant levels of
reductive glutathione (GSH) at the tumor site, imparting higher intracellular
concentration of the drug, and consequently increasing the inhibition of cell proliferation
[63][65]. Later, Ji et al. developed a simpler method for the preparation of the same
hybrid system. The PEG-SH was conjugated to GO-SH via disulphide linkage by using
only air as an oxidizing agent. Moreover, they conducted a comparative study of the
intracellular drug release and cytotoxicity between NGO-SS-PEG/DOX and NGOPEG/DOX, to prove that the rapid release of the drug from the NGO-SS-PEG conjugate
with a detachable PEG shell was very specific to the tumor’s relevant GSH levels,
therefore, it showed higher therapeutic effect than that of NGO-PEG. They also reported
GO-SS-PEG/DOX as an efficient chemo-photothermal therapy, by demonstrating the
effect of photothermia on the release of DOX from both hybrid formulations. The results
showed an accelerated release of DOX in the case of NGO-SS-PEG/DOX by heat and
hence, the disulphide linkage breakdown [66]. Liu et al., created the 3D version of the
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redox-responsive PEGylated G nanocarrier (GON-Cy-ALG-PEG) for the delivery of the
anti-cancer DOX. It was prepared by conjugating cytamine modified PEGylated alginate
brush to GO, via disulphide linkage. The system succeeded to achieve a targeted delivery
of DOX to the tumor site, showing very high cellular uptake, with no obvious toxicity up
to 200µg/ml. However, it was recently reported that the disulphide linkage of the
detachable PEG shell was also susceptible to degradation by enzymes, which led
researchers to take alternative strategies [63].
Gan et al. reported a novel nanocarrier, by covalent functionalization of GO with chitosan
(CS). CS is a natural polysaccharide, which is biocompatible and serves as a low
immunogenic drug carrier. Its solubility is affected by pH changes: it is poorly dispersible
in alkaline pH, but forms homogenous dispersions in acidic pH, which was relevant to the
release mechanism of the drug from the GO-CS carrier as a response to the acidic
environment of the tumor [63][67]. The GO-CS was demonstrated as a drug carrier for
water-insoluble anti-cancer camptothecin, exhibiting a very high aqueous stability and a
loading capacity of 20 % (w/w), which was twice that reported in the case of PEGylated
GO. The carrier also proved to be non-toxic to healthy cells and with remarkable
cytotoxicity to tumor cells [67]. To further increase the targeting property of the GO-CS
carrier, Yang et al. incorporated folic acid (FA) to the chitosan carrier (FA-CO), as a
targeting molecule for tumor cells with over-expressed folate receptors on their surface.
The cellular uptake of DOX was very high when compared to GO-CS [68]. Tang et al.
prepared the same hybrid, but in a one-step preparation method. The composite was
prepared by combining GO, folic acid and trimethychitosan (TMC) in a single system to
prepare a modified FA with TMC (FTMC), which spontaneously conjugated with GO via
self assembly [69].
FA functionalized GO was prepared by Lin at al. by a one-pot synthetic technique, taking
the advantage of the self-polymerization of Dopamine (DA). The anti-cancer DOX and
the targeting molecule (FA) were immobilized simultaneously during the polymerization
on the GO surface, the polymerization was controlled by only pH adjustment and
excluding any chemicals or organic solvents; hence this represented a simple, low cost
and eco-friendly approach. A 100% loading capacity of the active DOX was achieved,
and was released in a sustained manner depending on the dissociation of the H-bonds
between GO and DOX [47].
Wu et al. functionalized GO with a different targeting molecule: hyaluronic acid (HA),
which is a natural polysaccharide that exists in cellular matrix, connective tissues and
body fluids. The hybrid (GO-HA) selectively targeted the delivery of DOX to tumor cells
via receptor-mediated endocytosis through receptors such as cluster determinant 44
(CD44) and receptors for hyaluronic-mediated motility, which are highly expressed in
tumor tissues. The delivery efficiency was proved by the significant tumor suppression
after intravenous injection of mice by 40% and with no significant toxicity or
28

inflammatory reactions [70]. Song et al. prepared the same hybrid, but instead of loading
the DOX onto the prepared GO-HA as in the previous work, the GO was first loaded with
DOX via π-π stacking and H-bonding, and then conjugated to HA via H-bonding,
achieving a loading efficiency of 42.9% and an entrapment efficiency of 69.5% [62].

2.2.2. Delivery of active proteins:
The role of proteins in regulating gene expressions and cellular signals pathways, justifies
their potential in cancer therapy. Protein-based therapy has many advantages over the
conventional chemotherapy, such as less side effects and less immunogenicity. However,
the poor cellular uptake and enzymatic hydrolysis have restricted the use of active
proteins in biotherapy. Zhang et al. demonstrated the use of GO functionalized with PEG
(GO-PEG), that was previously developed by Dai et al., as a vector for the delivery of
active proteins; GO protected the protein from enzymatic hydrolysis and retained its
activity till it reached the cells. In this study the GO-PEG was loaded with bovine serum
protein (BSA) as a model protein via physisorption to investigate the loading and release
behavior. The loading capacity was very high, which was attributed to the high loading
surface of GO, with a gradual release of the protein in phosphate buffer solution. As for
the stability of the proteins, the GO-PEG/protein complex was investigated versus free
protein in presence of digesting enzymes. The complex showed an intact protein, owing
to the steric hindrance created by the GO that prevented the digesting enzymes to reach
the protein [71].
A different strategy for the delivery of proteins was established by Park et al. A pHsensitive poly(acrylic acid) (PAA) polymer was grafted to GO surface by in situ radical
polymerization to create GO-PAA for the oral delivery of protein in their active form
without being degraded. The PAA is a weak anionic polyelectrolyte polymer that is
greatly dependant on the surrounding pH: the polymer was protonated at low pH of the
upper GIT, causing its shrinkage and protein retention, while at high pH of the intestine it
was deprotonated, and swollen by the electrostatic repulsion between the chains, allowing
the protein to be released. This complex provided both high loading capacity and
protection of the protein via the pH-dependant behavior of the polymer [72].

29

2.3. Alendronate sodium delivery systems
A few approaches were adopted to overcome the unfavorable physiochemical properties
of alendronate sodium, such as poor membrane permeability and esophageal irritation.
One of such approaches was based on the use of liposomal nanoparticles as a delivery
system. The liposome improves the membrane adhesion, permeability and absorption of
hydrophilic drugs, but due to its instability against chemical and enzymatic degradation in
the intestine, Han et al. coated its surface with chitosan. The positive charges of chitosan
created a shield around the liposome preventing acids or enzymes from reaching the
liposome’s surface, and providing an additional advantage by decreasing the drug’s
leakage and minimizing contact with the esophagus. The chitosan also interacted with the
negatively charged mucus layer of the intestinal epithelial cells, increasing its resident
time in the intestine and hence its oral absorption and bioavailability [73].
Enteric coating of the liposomes is another technology that protects against gastric and
enzymatic attack. Hosny et al. prepared the enteric coated liposomes: first the liposomes
were prepared from a mixture of phosphatidylcholin, cholesterol and lecithin, with the
mass ratio of 4:3:1 to achieve the highest encapsulation efficiency (49.39%), integrity and
stability, and then the poly(meth)acrylate (Eudragit® S100) was added to impart enteric
coating. To further enhance the liposomal stability, a negatively or positively-charged
enhancer such as stearylamine (SA) and dicetyl phosphate (DO) respectively, were mixed
with the liposomal lipid components. The positively charged enhancer (SA) was found to
increase the encapsulation efficiency due to the attraction force between its positive
charges and the negatively charged alendronate sodium. In the case of the negatively
charged enhancer, there was a repulsion force with the negatively charged drug, however,
it had an attraction force with the Eudragit positive charges, improving its coating
efficiency and showing more resistance to the gastric and enzymatic attacks. Therefore,
the negatively-charged enteric-coated liposomes were shown to have optimum features
allowing for high bioavailability and protection against esophageal irritation [74].
Polymeric micro particles were also among the systems used to overcome the
gastrointestinal adverse effects associated with alendronate sodium oral intake. Cruz et al.
prepared polymeric micro-articles by spray drying of alendronate sodium with
poly(meth) acrylate (Eudragit® S100) and another with a blend of Eudragit® S100/methyl
cellulose, with mean diameter below 17 µm. Both formulations of micro particles had
high encapsulation efficiency, and showed a slow release of the drug, with more delay in
presence of methylcellulose. As a consequence of delayed release, the gastrointestinal
injuries were almost diminished [46].
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The potentials of solid lipid nanoparticles (SLNs) such as high drug loading, drug
stability and low toxicity have recently increased their use as a drug delivery system for
different administration routes. The SLNs have a lipid matrix that can incorporate
hydrophobic as well as hydrophilic drugs, and alendronate sodium were demonstrated by
Hadi et al. as the drug model. The alendronate sodium loaded SLNs were prepared by
simple hot homogenization technique: emulsification followed by solidification without
the use of organic solvents. Very high encapsulation efficiency (70-85%) was achieved,
and a sustained release of the drug was also achieved owing to the solid matrix of the
nanoparticles [75].
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3. Theoretical Background
This chapter presents the theories behind the characterization and the analytical
techniques used in this work, and which includes X-ray diffraction (XRD), Scanning
electron microscopes (SEM), Ultraviolet/Visible (UV/Vis), Fourier Transform Infrared
(FTIR) spectroscopy and Zetasizer analyzer.

3.1. X-ray diffraction (XRD)
X-rays were discovered by the physicist Wilhelm Röntgen in 1895, followed by Gordon
Darwin in 1912 who established the dynamic theory of X-ray scattering by a crystal
lattice. X-rays are electromagnetic radiations that lie in between gamma and ultraviolet
radiations in the electromagnetic spectrum. They have a wavelength range of 0.1-100 Å,
which is almost in the same range as that of the size of atoms, making them eligible for
studying and characterizing materials at the atomic level. XRD is used to obtain structural
information of crystalline samples such as unit cell lattice parameters, crystal phase
composition, degree of crystallinity, residual stress, texture and orientation [76][77][78].
To have a complete understanding of the technique, some important principles are to be
discussed first.

3.1.1. Principle of XRD:
A- X-ray generation
X-rays are electromagnetic radiations that occur whenever an electric charge accelerate or
decelerate. The wavelength used for the crystallographic detection is 0.5-2.5 Å, which is
associated with very high energy that enables the X-rays to penetrate through the sample
and detect the smallest inter-atomic distances, and that what makes it a very powerful
detection tool. Figure (3-1) is a Bohr model of an atom to explain the generation of Xrays. The nucleus is surrounded by shells hosting electrons, and when a beam of electrons
hits the target material at a very high speed, an electron in an inner shell (K-shell for
example) is ejected, leaving behind a positive hole which is then filled by an higher
energy electron (from the L or M shells for example). This electronic transition produces
two types of X-rays known as: Kα X-rays which are of very high intensity, and Kβ X-rays
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which are of lower intensity. Kα and Kβ reflect the transitions of electrons from L- to Kshell and from M- to K-shell respectively, and are very characteristic of the atomic
structure of the target material [77][79]. Table (3-1) shows the commonly used target
materials and their wavelengths.

Fig 3-1. Diagram of X- ray generation [70].

Table 3-1. Target materials used in X-ray tubes and their characteristic wavelengths [79].

Element

Wavelength (Å)

Mo
Cu
Co
Fe
Cr

0.7107
1.5418
1.7902
1.9373
2.2909

B- Crystals

Solid matter is classified into amorphous and crystalline solids. Amorphous solids lack
order in the arrangement of their units, which can be atoms, ions or molecules. On the
other hand, crystalline solids, which represents 95% of all solid materials, have their units
arranged in periodic arrays with long-range order. The unit cell is the smallest volume
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element, when repeated in three dimensions, defines the crystal structure. The unit cell is
described by three main axes: a, b and c where α, β and γ represent the angles in between,
as shown in figure (3-2). The variation in these parameters gives rise to seven different
shapes of unit cells as in table (3-2) [76][78][80].

Fig 3-2. Three dimensional unit cell [76].

Table 3-2. Different shapes of unit cells and their possible axis systems [80].

Crystal system
Cubic
Tetragonal
Hexagonal
Rhombohedral
Orthorhombic
Monoclinic
Triclinic

Axis system
a=b=c, α=β=γ=90º
a=b≠c, α=β=γ=90 º
a=b≠c, α=β=90 º γ=120 º
a=b=c, α=β=γ≠90 º
a≠b≠c, α=β=γ=90 º
a≠b≠c, α=γ=90 º β≠90 º
a≠b≠c, α≠β≠γ≠90 º

When parallel planes of atoms are intersecting the unit cell, they define orientations and
inter-planar distances through the Miller indices (hkl), which represent the reciprocals of
the intersections of each of the three axes in the unit cell. For example, in figure (3-3),
planes that cut the x-axis at a/2, b-axis at b and c-axis at c/3, are described by the Miller
indices (213) [79][80].

35

Fig 3-3. Parallel planes of atoms intersecting the unit cell [77].

-

X- ray scattering:

The units in a crystal are arranged in long-range periodic arrays, and upon hitting a
crystalline matter X-rays cause the electrons surrounding each atom in the periodic arrays
to oscillate, scattering the radiation. This scattered radiation is in phase, and constructive
interference is obtained, resulting in waves of high intensity [79][76][80][81]. These
diffraction patterns give information about the units arrangement within a crystal, helping
elucidate the crystal structure and presenting a fingerprint for each crystalline material
[78][81].
-

Bragg’s law:

Constructive interference of diffracted rays occurs when meeting certain geometric
conditions. This is expressed by Bragg’s law. The relationship between the diffraction
angles, X-ray wavelength and inter-planar space is represented as follows in equation (1)
[78]:
eq.1
where, n is the order of reflection (n=1), λ is the wavelength of the X-ray, d is the
distance between parallel planes, and θ is the angle of incident ( which is equal to angle
of reflection) [78].
The application of Bragg’s law is schematically presented in Figure (3-4). The incident
and reflected rays form an angle (θ) with the parallel planes separated by a spacing “d”.
for the reflected rays to be in phase, the length difference between their paths must be a
multiple of their wavelength [76][78][79].
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Fig 3-4. X-ray reflection from two parallel planes [81].

3.1.2. Instrumentation of XRD:
In X-ray powder diffraction, the sample should be grounded well into a fine and smooth
powder to have a homogenous and randomly oriented sample crystals, to obtain a random
distribution of all the possible planes that contribute to the production of constructive
reflections of the crystal structure. Large non-randomly oriented crystal sample will give
rise to variation of peak intensities [78][79][80][81].
The typical geometry used for powder XRD is the Bragg-Brentano one, presented in
Figure (3-5). The X-ray tube is stationary, the sample rotates at an angle theta (θ) from
the X-ray tube, while the detector rotates at an angle 2-theta (2θ) from the X-ray tube,
detecting the diffracted beams and recording the high intensity of constructive
interference when it occurs as per Bragg’s law (eq.1). When X-ray intensity is plotted
against the angle 2θ, as shown in Figure (3-6), the high intensity signals are those where
Bragg’s law is met, and which correspond to X-rays constructively reflected from planes
with different “d” values. The dimensions of the unit cell can also be determined
[78][79][80].
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Fig 3-5. The Bragg-Brentano geometry [76].

Fig 3-6. An example of XRD chart [79].

3.2. Ultraviolet/Visible (UV/Vis) spectroscopy
3.2.1. Principles of UV/Vis spectroscopy:
The absorption of electromagnetic radiation in the UV or Vis range causes an energy
change (ΔE) in the valence electrons of a molecule or an atom, leading to electronic
transitions when ΔE of the transition corresponds to the energy of the incoming radiation.
In this case, the incident radiation of this energy value will be absorbed by the sample,
and the remaining radiation will be transmitted [82][83][86].
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Absorbance is the measure of this absorbed radiation and is directly proportional to the
amount of absorbing species (atoms, ions or molecules) in a sample. This relation is
expressed by the Beer-Lambert as follows in equation (2):
eq.2

= ε × c×

Where (ε) is the molar absorption coefficient, a material specific constant, (c) is the
concentration of the absorbing species in the sample and (d) is the path length of the
radiation through the sample [82][83][86]. This relation then allows the determination of
unknown concentrations using calibration curves constructed using known
concentrations. Beer-Lambert law (eq.2) however is only applicable in low concentration
ranges, and at higher concentrations, the linearity between Absorbance and concentration
no longer holds.

3.2.2. Instrumentation of UV/Vis spectroscopy:
There are two types of UV/Vis spectrophotometers: single-beam and double-beam
spectrophotometers. The simple single-beam set up as shown in figure (3-7) has a single
optical path from the source to the detector, using a fixed-wavelength monochromator. It
requires calibration every time before measuring the sample. The advantage of this set up
is that it is relatively inexpensive and easily transported, but on the other hand the
recalibration process is time-consuming and the spectrophotometer is less accurate than
the double-beam spectrophotometer [83]. It is therefore useful for measurements at a
particular value of wavelength.

Fig 3-7. Schematic diagram of single-beam spectrophotometer setup [83].
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As for the double-beam spectrophotometer in figure (3-8), the setup comprises the
radiation source, followed by a monochromator to select the required wavelength falling
onto the sample. The beam is split into two equal parts by a half mirror to simultaneously
pass through a blank and the sample. The detector collects both beams, determining the
sample Absorbance at this particular wavelength. When the Absorbance is plotted against
wavelength values as in figure (3-9), the Absorbance spectrum of the sample is obtained
where the wavelength of the highest Absorbance represents λ max, which is characteristic
for each substance. The double-beam setup is more expensive but more versatile and
accurate than the single-beam setup [82][83][86].

Fig 3-8. Schematic diagram of double-beam spectrophotometer setup [82].

Fig 3-9. An example of a UV spectrum [86].
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3.3. Fourier transform Infrared (FTIR) spectroscopy
3.3.1. Principles of FTIR:
FTIR spectroscopy gives important information about the sample’s identity and the
number of components in a sample mixture [87]. For a sample to absorb IR radiation, the
radiation must induce molecular vibration associated with a change in the dipole moment
of a molecule in the sample. When the energy of the molecular vibration is equal to that
of the IR radiation, absorption takes place. A general model in figure (3-10) represents
the molecular system as atoms connected to each other by a spring-like bonds that expand
and contract as a response to the vibrational frequencies [90][91].

Equilibrium
bond length

Stretched

Compressed

Fig 3-10. Changes in the dipole moments of a diatomic molecule [91].

The atoms are continuously moving relative to each other around their central atom in
two common vibrational modes: stretching and bending. In the stretching mode, a change
in the bond length takes place. Stretching can be classified into symmetric (in-phase
stretching) and asymmetric (out-of-phase stretching) modes (figure 3-11.a). In bending
modes, a change in the angles between the atoms occurs. Bending is classified into
rocking, scissoring, wagging and twisting (figure 3-11.b). Since the change of the
molecular dipole moment is a must for IR-radiation absorption to take place, the greater
the change, the higher is the absorption intensity. The stretching mode represents the
most detectable and useful peaks in the IR spectrum, because stretching the bonds
between two atoms of different electronegativities greatly changes the dipole moment
[90][91][92].
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(a)

(b)
Fig 3-11. Stretching (a), and bending vibration (b) modes [93].

The frequency of the vibrational modes can be calculated mathematically when the
stretching vibration is approximated by Hooke’s law, that is derived from the simple
harmonic oscillator model. The frequency (υ) of the vibration is related to the force
constant ( of the spring and the reduced masses of the atoms ( as follows in equation
(3) [88][89][90]:
k

υ=

eq.3

The value of the reduced masses is calculated as follows from equation (4) where
2 are the masses of involved atoms [88][89][90]:
μ=

1

2/

1+

2)

1 and

eq.4

And to have a direct use of the wavenumber values of the vibrational frequencies, the
first equation is modified as follows in equation (5):
ῡ=

k

eq.5

where ῡ is the wavenumber and c is the speed of light [88][89][90].
When applied to a molecule in a sample this model leads to different vibrational modes of
the different functional groups constituting the molecule. This leads to the absorption of
the radiation of energies equal to the energies of each of these vibrational modes, leading
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to a spectrum for the sample, with absorption bands characteristics of the different
functional groups present and their structural arrangement. In this respect a IR spectrum
of a species helps elucidate structural details [90][91].

3.3.2. Instrumentation of FTIR:
FTIR spectrophotometry (figure 3-12) relies on an “interferometer”, which by turn is
equipped with a beam splitter that splits the incident infrared beam into two: one reflects
off of a fixed flat mirror at a fixed path length and the other from a mirror that moves at
short distances to create a path difference between the two beams. These two reflected
beams are then combined and interfered via the interferometer to include every single
data about the incoming infrared frequency in a simultaneous fast manner. The produced
signal is interpreted, through the application of a Fourier Transform resulting in a spectral
plot of intensity versus wavenumber/frequency, reflecting the absorbing species structural
information [87][95].

Fig 3-12. Principle of FTIR spectrometer operation [95].
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The analyzed samples could be a liquid, solid or gas. Sample holders (for liquids and
gases) must be IR transparent and are typically composed of a alkaline metal halide. Solid
samples are typically prepared by the KBr pellet technique where a mixture of 2-3 mg of
the sample with 0.5-1 g of KBr is pressed into a transparent disk [96].

3.4. Scanning Electron Microscopy (SEM)
The SEM was invented 50 years ago, and now is a widely used scientific technique in
metallurgy, geology, biology, medicine and many other fields, since it is capable of
providing a nano-scale resolution with a good depth of field, giving information about the
morphology, structures and chemical compositions and many other features [97][98].

3.4.1. Principles of SEM:
The SEM generates an accelerated beam of electrons from a suitable cathode source that
passes through a set of condenser and objective lenses to decrease its cross section. The
spot-like electron beam scans the surface of the sample in a vacuumed atmosphere, and
an image is formed by collecting various signals reflected from the different interactions
between the electron beam and the sample [97][98][99].
There are two types of interactions that are responsible for an image formation: elastic
and inelastic interactions. In the elastic interactions, electrons are generated from the back
scattering of the incident electron beam by the outer electrons of a sample specimen
having the same energy, at an angle greater than 90°, and giving an image of the sample’s
depth. In inelastic interaction, the incident electron beam interacts with the specimen’s
outer electrons, leading to the generation of secondary electrons from a depth of 5 nm
below the surface, giving an image of the sample surface. In addition, other signals
generated from the interaction between the electron beam and the sample such as X-ray
emission, Auger electrons and cathodoluminescence can be used for additional
compositional information about the sample, as shown in figure (3-13) [99][100][101].
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Fig 3-13. Illustration of the different signals obtained from hitting the sample specimen with the incident
electron beam [99].

3.4.2. Instrumentation of SEM:
The SEM (figure 3-14) is equipped with an electron gun that produces an electron beam
at a high voltage, with a small spot size and low energy dispersion. The electron beam
then passes through the anode aperture into a lens system that focuses it onto the sample.
The sample is placed in a chamber at high vacuum so as to prevent specimen
contamination and interference of gas phase scattering. To obtain a clear image, the
samples must be electrically conductive; because they exhibit high electron density,
increasing the emission of secondary electrons, that are responsible for producing a
strong image, and otherwise, it is sputter-coated with a conductive metal such as gold,
silver or palladium [97][100][101].
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Fig 3-14. Diagram of the scanning electron microscope (SEM) [100].

3.5. Zetasizer analyzer
3.5.1. Principle of Zetasizer:
The Zetasizer analyzer is capable of measuring both the size and zeta potential of a
particle.
The zetasizer measures the zeta potential, by applying an electric field to the liquid in
which the particles are suspended (electrophoresis). These particles would move towards
the electrode of opposite charges (attractive force), and the viscosity of the liquid
surrounding the particles will act as an opposing force, resulting in an equilibrium state,
that ends up in the particles moving at a constant velocity. This velocity is known as
electrophoretic mobility, which is measured directly by an equipped laser technique
called Laser Doppler Velocimetry (LDV) [102][103]. The electrophoretic mobility is
translated to zeta potential by applying Henry’s law (equation 6) as follows:
eq.6
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Where, ʑ is the zeta potential, UE is the electrophorectic mobility,
η viscosity, and ( ) is Henry’s function (≈1) [102][103].

is dielectric constant,

As for particles’ size function, which is the main concern in this research is to be
elaborated in details. The zetasizer measures the particle sizes via dynamic light
scattering (DLS) technique, which measures the particles’ Brownian motion (collision of
particles with the surrounding liquid) and relates it to their sizes. It begins by directing a
laser onto the particles, which by turn scatters the light. The scattered light is then
collected at a screen held close to the particles, to give a speckle pattern of bright and
dark areas as in figure 3-15. To determine the particle sizes, the DLS compares first the
intensity signals of a particular part of the speckle at a time point (t), to another signal at a
later time (t+ δt), but over a very small time scale in the order of 1 to 10’s milliseconds,
in order to have a good correlation between the signal intensities over time. However, the
suspended particles are not stationary due to Brownian motion, which leads to fluctuation
of the intensities of the bright and dark areas in the speckle pattern. Therefore, the size
particle is related to the rate of correlation decay: where small particles have fast
correlation decay than large ones as seen in figure 3-16, because of their motion speed
differences [102][103].

Fig 3-15. A screen with a speckle pattern of bright and dark areas [102].
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Fig 3-16. Correlation function of small and large particles over time [102].

The Zetasizer software uses algorithm to use the collected information of the correlation
function to calculate the size distribution and displays it in the form of a graph as shown
in figure 3-17, where X-axis represents the size distribution and Y-axis represents the
relative intensity of scattered light [102][103].

Fig 3-17. A typical size distribution graph [102].
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3.5.2. Instrumentation of Zetasizer:
The DLS system consists of six main parts (figure 3-18): the laser source, which
illuminate the particles that are suspended inside a cell. The intensity of the scattered light
is then measured by the detector. However, the intensity of light should be within a
certain range for the detector to measure, therefore, the system is equipped with an
attenuator to adjust the intensity of the scattered light. The scattered light is then passes to
a digital signal processor know as a correlator; which detects the correlation between the
signal intensities at successive time intervals. The correlation information is then
transferred to the computer to produce a size distribution related data [102][103].

Fig 3-18. A schematic description of the Zetasizer analyzer [102].
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4. Materials and Methods
4.1. Materials
High purity materials were purchased. Zinc nitrate hexahydrate (98%), Aluminum nitrate
nonahydrate (≥98%), Sodium hydroxide (≥98%), sulfuric acid (95-97%), hydrochloric
acid (37%), potassium permanganate (> 99%), copper sulphate pentahydrate (>98%),
acetic acid (99.8%) and Phosphoric acid (85 %) were purchased from Sigma-Aldrich
(Germany). Graphene nanopowder (11-15 nm) was purchased from SkySpring
Nanomaterial (USA). Hydrogen peroxide (30%) was purchased from Merck (Germany),
sodium acetate trihydrate (99.7%) was purchased from Fischer scientific, and ethanol
(99.9%) was purchased from Carlo Erba (Italy). Alendronate sodium in trihydrate form
(97%) was purchased from Alfa Aesar (Germany).

4.2. Preparation of pristine LDHs
Two different cationic ratios of Zn-Al LDH: (Zn2+: Al3) of 2:1 and 3:1, in their nitrate
forms were prepared, by co-precipitation, following the procedure described elsewhere
[104]:
The two Zn-Al-NO3 LDH systems were prepared by mixing 0.1 M Zn(NO3)2.6 H2O with
0.1 M Al(NO3)3.9 H2O, with ratios of 2:1 (30 ml:15 ml) or 3:1 (30 ml:10 ml). The
mixture was then co-precipitated at room temperature and while maintaining the pH at 7,
by the drop-wise addition of 2 M NaOH [1][6]. The mixture was magnetically stirred
throughout the reaction, with nitrogen gas bubbling into the mixture solution to expel any
dissolved carbon dioxide and thus preventing the intercalation of carbonate ions. The
produced precipitate was then filtered using Whatman® filter paper, grade 1, with 11 μm
pore size, followed by washing several times with de-ionized water to remove any
impurities. The precipitate was then dried at 80°C overnight. This resulted in samples
Zn2-Cp and Zn3-Cp for the 2:1 and 3:1 Zn2+:Al3+ LDH compositions respectively.
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4.3. Oxidation of G powder
The oxidation of G followed the modified Hummer’s method with slight modifications
[18]. A 9:1 mixture of concentrated H2SO4/H3PO4 (360 ml:40 ml) was added to a mixture
of G (3 g.) and KMnO4 (18 g.). The mixture was heated to 50°C, and then magnetically
stirred for 12 hours. The mixture was then cooled to room temperature, poured to 400 ml
of crushed ice (to have a mixture of the ice, G and acids), and then 3 ml of 30% H2O2 was
added to it. It was then passed through a metal sieve (pore size: 300 μm) to remove any
impurities or aggregates, centrifuged (Fischer Scientific Centrific Model 228) for one
hour at 1129 rpm (RCF (10)=1.12×Radius(7mm)×(rpm/1000)2), and the supernatant was
decanted. A purification process was then carried out on the solid product by successive
washing with 200 ml deionized water, 200 ml 37% HCL, and twice with 200 ml ethanol.
After each wash, the mixture was centrifuged and the supernatant was decanted. The
resultant solid material was dried in a vacuum oven overnight [18].

4.4. Preparation of G and GO/LDH hybrids
Hybrids of G and GO/Zn-Al-NO3, were prepared by co-precipitating the LDH in the
presence of a dispersion of the G or GO. The choice of weight percentage (% w/w) of G
or GO in total hybrid weight, and the concentration of the intercalating solution were
based on their effect on the crystallinity of the LDH hybrid.

4.4.1. Determining the optimum GO weight percentage in the hybrid
(%w/w):
In this step, different % wt of GO were intercalated into the co-precipitated Zn-Al-NO3
LDH with cationic ratio (Zn2+/Al3+) of 2:1.

Procedure
Solutions A: 10 mg, 30 mg, or 70 mg of GO were first sonicated in small volumes of
deionized water, till complete dispersion was achieved and a light brown suspension was
obtained. The volumes were then completed to 250 ml with deionized water.
52

Solution B: A mixture of the metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O
and ml 0.1 M Al (NO3)3.9 H2O with a ratio of 2:1 (30 ml:15 ml).
Solution B was then added drop wise to each of solutions A together with dropwise
addition of 2 M NaOH at room temperature and while maintaining a pH 7 [1][6].The
mixtures were magnetically stirred throughout the reaction, with nitrogen gas bubbling
into the mixture solution to expel any dissolved carbon dioxide and avoid the
intercalation of carbonate ions. The produced precipitates were then filtered using
Whatman® filter paper, grade 1, with 11 μm pore size, washed several times with deionized water to remove any impurities and dried overnight in the oven at 80°C. This
resulted in LDH-GO hybrids with 2 % wt (for 10 mg GO dispersed in solution A), 6.2 %
wt, (for 30 mg GO dispersed in solution A), and 13.4 % wt (for 70 mg GO dispersed in
solution A) of GO.
The 2 % wt GO showed the best XRD results, regarding the crystallinity of the LDH as
would be discussed in the following chapter, and was thus chosen for the preparation of
all LDH-GO and LDH-G hybrid samples.

4.4.2. Determining the optimum volume for the G and GO dispersion
solutions for the preparation of the LDH-G and LDH-GO
hybrids:
The LDH hybrid composition as selected to be 2% (w/w) in G or GO, as explained above.
Different volumes for the G and GO dispersion solutions were investigated for the
formation of the LDH-G and LDH-GO hybrid to identify the optimum volumes. Both
metal cationic ratios (Zn2+:Al3+) of 2:1 and 3:1 for the LDH were used. Table 4-1,
summarizes the amounts and volume for different samples used in this investigation.
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Table 4-1. G and GO/Zn-Al-NO3 hybrids prepared with different concentrations of the G and GO
suspension/solution.

Amount of dispersed G (mg/ml)

Amount of dispersed GO (mg/ml)

Molar ratio
( M2+: M3+)
for the LDH
0.04

0.1

0.2

0.4

0.04

0.1

0.2

0.4

2:1

Zn2G.04-Cp

Zn2G.1-Cp

Zn2G.2-Cp

Zn2G.4-Cp

Zn2GO.04-Cp

Zn2GO.1-Cp

Zn2GO.2-Cp

Zn2GO.4-Cp

3:1

Zn3G.04-Cp

Zn3G.1-Cp

Zn3G.2-Cp

Zn3G.4-Cp

Zn3GO.04-Cp

Zn3GO.1-Cp

Zn3GO.2-Cp

Zn3GO.4-Cp

Procedure:
Solutions A: different amounts of G or GO were used for the suspension in different
volumes: 0.04, 0.1, 0.2, 0.4 mg/ml in 250, 100, 50 and 25 ml volumes respectively. The
G or GO was first sonicated in small volume of deionized water to obtain a homogenous
suspension, free of agglomerates in case of G, and a clear light brown suspension in case
of GO, and then the volumes were completed with deionized water.
Solution B: a mixture of the metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O
and ml 0.1 M Al (NO3)3.9 H2O with a ratio of 2:1 (30 ml:15 ml) or a ratio of 3:1 (30
ml:10 ml).
Solution B was added dropwise to each of solutions A together with dropwise addition of
2 M NaOH at room temperature and while maintaining a pH 7 [1][6]. The mixtures were
magnetically stirred throughout the reaction, with nitrogen gas bubbling into the mixture
solution to expel any dissolved carbon dioxide and avoid the intercalation of carbonate
ions. The produced precipitates were then filtered using Whatman® filter paper, grade 1,
with 11 μm pore size, washed several times with de-ionized water to remove any
impurities and dried overnight in the oven at 80°C. This resulted in LDH-G and LDH-GO
hybrids with 2 % wt of G or GO, as per Table (4-1).
As the different volumes of G or GO dispersion solutions did not show any impact on the
hybrid samples produced, regarding differences in crystallinity (as would be discussed in
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the following chapter), the largest solution volume (corresponding to the lowest
dispersion concentration) would be therefore used. This larger volume would ensure
easier dissolution of the drug to be loaded in these hybrids.

4.5. Loading of alendronate sodium
Alendronate sodium was loaded into the different host systems: pristine Zn-Al-NO3
LDHs and the LDH-G and LDH-GO hybrids, and the different loading efficiencies of
each of the systems investigated. Drug loading was conducted by co-precipitation and
ion-exchange, as described elsewhere [104].

4.5.1. Co-precipitation:
Table 4-2 The intercalated systems with alendronate sodium prepared by co-precipitation.

Drug’s name

Drug’s molar
concentration

Molar ratio
(M2+: M3+)

2:1
Alendronate
sodium

0.002 M
3:1

Intercalated system

Sample code

Zn-Al-NO3
Zn-Al-NO3/G
Zn-Al-NO3/GO
Zn-Al-NO3
Zn-Al-NO3/G

A-Zn2-Cp
A-Zn2-G-Cp
A-Zn2-GO-Cp
A-Zn3-Cp
A-Zn3-G-Cp

Zn-Al-NO3/GO

A-Zn3-GO-Cp

Procedure:
A- Preparation A-Zn2-Cp and A-Zn3-Cp hybrids:
Solution A: known amount of alendronate sodium (0.0005 moles) was dissolved in a
total volume of 250 ml of deionized water to have a drug concentration of approximately
0.002 M.
Solution B: a mixture of metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O and 0.1
M Al (NO3)3.9 H2O with a ratio of 2:1 (30:15 ml) for A-Zn2-Cp, or a ratio of 3:1 (30:10
ml) for A-Zn3-Cp.
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Solution B was added dropwise to solution A together of dropwise addition of 2 M NaOH
at room temperature and while maintaining a pH 7 [1][6]. The mixtures were
magnetically stirred throughout the reaction, with nitrogen gas bubbling into the mixture
solution to expel any dissolved carbon dioxide and avoid the intercalation of carbonate
ions. The produced precipitates were then filtered using Whatman® filter paper, grade 1,
with 11 μm pore size, washed several times with de-ionized water to remove any
impurities and dried overnight in the oven at 80°C. This resulted in samples A-Zn2-Cp
and A-Zn3-Cp as presented in Table (4-2).

B- Preparation of A-Zn2-G-Cp, A-Zn3-G-Cp, A-Zn2-GO-Cp, and A-Zn3-GOCp:

Solution A: a known amount of alendronate sodium (0.0005 moles) was dissolved in a
total volume of 250 ml of deionized water to have a drug concentration of approximately
0.002 M. An amount of G or GO was dispersed in the drug solution to result in a 2%wt of
G in the LDH-G hybrid or of GO in the LDH-GO hybrid. The mixtures were sonicated
till a homogenous, agglomerate-free suspension was produced in the case of G, and a
clear light brown solution was obtained in the case of GO. The mixture was then left to
stir for 24 hours.
Solution B: a mixture of metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O and
0.1 M Al (NO3)3.9 H2O with a ratio of 2:1(30 ml:15 ml) for A-Zn2-G-Cp and A-Zn2-GOCp or a ratio of 3:1 (30 ml:10 ml) for A-Zn3-G-Cp and A-Zn3-GO-Cp.
Solution B was added dropwise to solutions A together of dropwise addition of 2 M
NaOH at room temperature and while maintaining a pH 7 [1][6]. The mixtures were
magnetically stirred throughout the reaction, with nitrogen gas bubbling into the mixture
solution to expel any dissolved carbon dioxide and avoid the intercalation of carbonate
ions. The produced precipitates (containing the drug) were then filtered using Whatman®
filter paper, grade 1, with 11 μm pore size, washed several times with de-ionized water to
remove any impurities and dried overnight in the oven at 80°C. This resulted in samples
A-Zn2-G-Cp, A-Zn2-GO-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp as presented in Table (42).
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4.5.2. Ion- exchange:
Table 4-3. The intercalated systems with alendronate sodium prepared by ion-exchange.

Drug’s name

Drug’s molar
concentration

Molar ratio
(M2+: M3+)

2:1
Alendronate
sodium

0.01 M
3:1

Intercalated system

Sample code

Zn-Al-NO3
Zn-Al-NO3/G
Zn-Al-NO3/GO
Zn-Al-NO3
Zn-Al-NO3/G

A-Zn2-IE
A-Zn2-G-IE
A-Zn2-GO-IE
A-Zn3-IE
A-Zn3-G-IE

Zn-Al-NO3/GO

A-Zn3-GO-IE

Procedure:
A known amount of alendronate sodium (0.0005 moles) were dissolved in a total volume
of 50 ml of deionized water to have a drug concentration of approximately 0.01 M. It is
important to note that a smaller total volume with a higher concentration of the drug was
used for the ion-exchange (as compared with that used for co-precipitation) in order to
allow for an efficient ion-exchange process.
Portions of 100 mg of previously prepared Zn2-Cp, Zn3-Cp, Zn2-G.04-Cp, Zn2-GO.04Cp, Zn3-G.04-Cp and Zn3-GO.04-Cp were dispersed in the drug solution and sonicated
till complete dispersion (when a white suspension is formed and no solid residues), the
pH was then adjusted to 7 by the dropwise addition of 2 M NaOH [1][6]. The mixtures
were magnetically stirred under nitrogen bubbling into the mixture for 24 hours to allow
ion-exchange to take place. The produced suspensions were then vacuum filtered through
a Whatman® nylon filter membrane of pore size 0.45 μm, in order to prevent the loss of
the low yield precipitates, which were then dried overnight in the oven at 80 °C. This
resulted in samples A-Zn2-IE, A-Zn2-G-IE, A-Zn2-GO-IE, A-Zn3-IE, A-Zn3-G-IE, and
A-Zn3-GO-IE, as presented in Table (4-3).
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4.6. Characterization
The pristine LDHs, LDH-G, LDH-GO systems, and the drug-loaded systems were
characterized by XRD, FTIR, SEM, and Zetasizer analyzer, while the loaded and released
drug from the systems were quantified by UV/Vis spectrophotomerty.

4.6.1. Powder X-ray Diffraction (PXRD):
The powder X-ray diffraction patterns of the samples were obtained using a D8 Bruker
X-ray diffractometer, which was operated at 40 KV and 30 mA, and using Cu as the
anode target, producing Kα-X-rays of high intensity with a wavelength of 0.1542 nm.
The patterns were detected at 2-theta range between 3° to 80° with a step size of 0.030°,
and a step time 3 seconds.

4.6.2. Fourier Transform Infrared Spectroscopy (FTIR):
The FTIR spectra of the samples were obtained using a Thermo-scientific Nicolet 380
Fourier Transform Infrared spectrophotometer, using the KBr pellet method. The KBr
pellets were prepared by grinding and mixing a ratio of 1:100 (sample mass: KBr mass),
which was then compressed by a hydraulic pressure at a pressure of 1400 KPa. The FTIR
spectra obtained presented a plot of wave number (4000-500 cm-1) against %
transmittance.

4.6.3. Scanning Electron Microscope (SEM):
The morphological images of the samples were obtained by using Leo Zeiss supra field
emission scanning electron microscope (FESEM). The instrument was operated at 23
KV. The samples were conductive due to the presence of Zn and Al metals in the LDH
and graphene, and therefore, there was no need for a coating layer.

4.6.4. Ultraviolet/Visible (UV/Vis) spectroscopy:
The amount of drug loaded or released was quantified using a Varian Cary 500 UV-Vis
NIR double-beam spectrophotometer. The absorbance of the drug loaded was detected at
λmax of 228 nm, while that of released drug was detected at 233 nm. The drug solution
concentration values were determined from pre-constructed calibration curves (please
refer to Appendix A).
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Alendronate sodium lacks a detectable chromophore, which makes it difficult to be
directly detected. However, since, alendronate sodium exhibits a metal-complexing
property, derivatization of alendronate sodium by introducing a UV- active metal is
typically used to allow its spectroscopic detection. Alendronate sodium forms a stable
complex with copper (II) (Cu2+) ions, in acidic medium, having a 1:1 stoichiometry, that
is detectable by UV/Vis spectrophotometry, which is presented as follows in equation (7):
ABP + Cu 2+

ABP-Cu

eq.7

Where ABP stands for alendronate sodium bisphosphonates [107][108]. As long as the
concentration of the alendronate sodium in the sample is higher than that of Cu2+, the
increase in the absorbance is proportional to the increase in concentration of ABP-Cu
complex, but at higher concentration of Cu2+, alendronate sodium is saturated with Cu2+,
and the increase in absorbance is only proportional to the increase in the concentration of
Cu2+ [108]. However, at constant concentration of Cu2+, the saturation effect is negligible
over a limited concentration range of alendronate sodium, and a linear relation between
the absorbance and the concentration of alendronate sodium is obtained. Therefore, for
the determinations here, the drug was derivatized as described by Walash et al. [107]. 2
ml of a 2 mM copper (II) sulfate solution together with 2 ml of 5 mM acetate buffer (pH
5, adjusted with acetic acid) were added to 2 ml of the alendronate sodium solution. The
volume was completed to 25 ml using deionized water. In case of concentration
determination in SGF (simulated gastric fluid), 2 ml of SGF were added to the solution
mixture before completing to 25 ml. The concentration of alendronate sodium solutions
to be detected were always kept in the range of 2-40 μm [107][108].

4.6.5. Zetasizer analyzer
The particles size of the prepared samples were determined by Zetasizer analyzer (Image
3-1) (Nano-ZS90) from Malvern Instruments. Very small amount of the sample powder
were dispersed in about 1ml deionized water and then analyzed by dynamic light
scattering, with 90° scattering optics at room temperature.
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4.7. Determination of alendronate sodium loading
The loaded amount of drug, which includes both intercalated and adsorbed species, was
determined based on the fact that LDH is degradable in acidic media (stomach), and
therefore, the loaded drug could be recovered and detected after dissolving the LDH in
acid [105]. A known mass (50 or 100) mg of the drug-loaded systems were dissolved in
a 10 ml of stimulated gastric fluid (SGF). The SGF stock was prepared according to the
United States pharmacopeia (USP) 29: 2 g sodium chloride and 7 ml HCl were mixed
together and the volume completed to 1000 ml by deionized water. The final pH was 1.2.
The free drug was then detected by UV/Vis spectrophotometer at λmax 228 nm, and the
concentration was determined using a pre-constructed calibration curve in SGF (please
refer to Appendix A), following the procedure described in section 4.6.4.

4.8. In- vitro drug release
The in-vitro release study of alendronate sodium was performed in water medium as
described in USP 29 for alendronate sodium solid dosage form. The dissolution
procedure, needed to apply sink conditions. These are defined in the USP 29 as the
volume of medium at least three times that required to form a saturated solution of the
drug. Taking in consideration that the solubility of alendronate sodium in water is 10
mg/ml [106], a known mass of the loaded system (50 to 100 mg with predetermined drug
loaded amounts) was suspended in 10 ml deionized water, and placed in a thermostated
water bath shaker at 37 °C and 50 strokes/min. The absorbance of the released drug was
detected at different time intervals
( 0.16, 0.5, 1, 2, 4, 6, 18, and 24 hrs) with UV/Vis spectrophotometer at λmax 233 nm, and
the concentration was determined using a pre-constructed calibration curve in deionized
water (please refer to Appendix A), following the procedure described in section 4.6.4.
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5. Results and Discussion
5.1. Pristine LDHs
5.1.1. XRD:
Figure 5-1 presents the XRD spectra for Zn2-Cp and Zn3-Cp, showing their successful
preparation by co-precipitation, that is emphasized by the presence of the characteristic
reflections for LDHs. These reflections are divided into two main types: strong basal and
intense reflections at low 2θ angles, and other asymmetric broader reflections at higher 2θ
angle values [1][6][109]. The sharp reflections are associated to diffraction by planes
(003), (006), and (009). The basal spacing d(003), which is equal to one interlayer distance
plus the thickness of one brucite-like layer can be calculated directly from the peak
position of the (003) peak using Bragg’s law (equation.1, sector 3.1.1). Thus, the exact
interlayer distance is easily calculated by subtracting the thickness of the brucite-like
layer (estimated as 4.77 Å as stated by Miyata) [110]. These reflections are also useful in
calculating the lattice parameter (c) from either the position of the first peak (equation 8
and 9):
c꞊ 3d(003)

eq.8

or the average of the three peak positions:
c=d(003)+ 2d(006)+ 3d(009)

eq.9

The (009) reflection is usually overlapped with non basal reflections and broad due to
disorders of the interlayer anions and water molecules. While the reflections at higher
angle values (around 2 θ≈ 60º), are useful for the determination of the lattice parameter
(a): as a= 2d(110); whose value is equal to the distance between two metal cations, and
thus, reflecting the radii of the cations [1]. As for the characteristic reflections at the
intermediate angles: (012), (015) and (018), these are used to determine the stacking
sequence of the layers, and with the values of a and c, are indexed as 3R stacking
polytype with hexagonal symmetry [1].
The prepared samples showed the as-mentioned characteristic reflections, agreeing with
literature [111], and their lattice parameters, d-spacing and interlayer distances are
summarized in table (5-1) . The (003) reflection in the case of Zn2-Cp had shifted slightly
to a lower 2 θ (≈9.7 º) than that of Zn3-Cp (≈ 10.3 º), giving d-spacing values of 9.1 Å
and 8.6 Å respectively. Since, c value is greatly dependent on the size, charge and the
orientation of the interlayer anions, it increases with the increase of the interlayer
distance. In this case, the increase in the basal spacing was due to the decrease of the
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metal cations ratio (high x value), indicating higher positive charge density in the brucitelike layers, accommodating more nitrate anions to neutralize the positive charges. These
cannot fit in a parallel manner in the interlayer space and hence, are tilted, giving slightly
larger d-spacing and c value [111][112]. The increase of the charge density in sample
Zn2-Cp is also reflected on the increase of the peaks’ intensities compared to sample
Zn3-Cp, with a very good agreement with literature reported by Seftel et al [112]. On the
other hand, the value of parameter (a) for both samples is almost the same, which
indicates its independency of the metal cationic ratio [6].

Fig 5-1. XRD patterns of Zn2-Cp (a), and Zn3-Cp (b).

Table 5-1. The lattice parameters, d-spacings and interlayer distances of Zn2-Cp and Zn3-Cp.

Sample

d spacing (Å)
d(003)

Lattice parameters
(Å)
c

d(110)

Interlayer
distance (Å)

a

Zn2-Cp

9.1

1.53

27.3

3.06

4.33

Zn3-Cp

8.6

1.52

25.8

3.04

3.83
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5.1.2. FTIR:
Figure 5-2 shows the IR spectra of Zn2-Cp and Zn3-Cp. Both show a broad absorption
band at around 3400 cm-1, which is attributed to the stretching vibrations of the hydroxyl
groups (O-H) in the brucite-like layers or the adsorbed water molecules [6][113]. The
peak 1612 cm-1 is due to the H-O-H bending vibration of the interlayer water molecules.
A very sharp characteristic peak at 1384 cm-1 is attributed to the nitrate group vibration
[113]. Peaks showing at low frequency regions: around 800, 600 and 426 cm-1, are
attributed to vibrations of the metal-oxygen (M-O) and metal-oxygen-metal (M-O-M)
bonds in the brucite-like layers [113].

Fig 5-2. FTIR spectra of Zn3-Cp (a) and Zn2-Cp (b) pristine LDHs.
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5.1.3. SEM:
Figure 5-3 shows the SEM image of the general structure of Zn-Al-NO3 LDHs, clearly
showing the flake-like structure of the layers [114].

Fig 5-3. SEM image of pristine Zn-Al-NO3 LDH.
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5.2. Oxidation of G powder

5.2.1. XRD:
The successful oxidation of G into GO sheets, using improved Hummer’s method, was
proven by the appearance of GO characteristic XRD reflections as shown in figure (5-4).
Prior to oxidation, the G showed a very sharp (002) peak at 2θ≈26.15°, having an
interlayer spacing of 3.4 Å. Post-oxidation, the (002) peak was greatly shifted to a lower
2θ value of 9.1°, having an interlayer spacing of 9.7 Å. This increase in the interlayer
spacing is attributed to the introduction of oxygenated functional groups at both sides of
the G sheets. The small broad peaks at higher 2θ values indicate the presence of traces
from the starting G powder [17][21][23].

Fig 5-4. XRD patterns of G (a), and GO (b).
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5.2.2. FTIR:
As shown in figure 5-5, some important vibration bands appeared upon G oxidation, that
are related to the introduced oxygenated groups. These vibrations are: O-H stretching
vibration, appearing at around 3400 cm-1. These hydroxyl groups are attributed to both
carboxylic acid groups (COOH) and adsorbed water molecules, the band at 1612 cm-1 is
also an indication of the O-H bending vibration of the adsorbed water molecules. Bands
appearing at 1726 cm-1 is attributed to C=O stretching vibrations, from COOH, ketone or
quinone groups. C-O vibration appears at 1228 cm-1, and C-O-C stretching vibration
appears at 1170 cm-1 [20][21][23].

Fig 5-5. FTIR spectra of G (a) and GO (b).

5.2.3. SEM:
Figure 5-6 represents the SEM images for the surface morphology of G prior and post
oxidation. Prior oxidation, G, showed aggregations of several stacked layers, giving rise
to a rough surface appearance. While, post-oxidation the surface of GO sheets was
smoother, showing less aggregates, and very few stacked layers; which indicates the
successful exfoliation of the G by its oxidation [17][20][21][23].
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a

b

Fig 5-6. SEM images of G (a), and GO (b).
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5.3. Preparation of G/GO-LDH hybrids

5.3.1. Determining the optimum GO weight percentage in the hybrid
(%w/w):

Figure 5-7 shows the XRD patterns of GO-LDH hybrids, prepared using LDH with
M2+/M3+ ratio of 2:1 and different % wt of GO (2, 3.2, and 13.4 % wt). The intensity of
the reflections at plane (003) and (006) become less intense and broader with the increase
of the % wt of GO (2, 6.2, and 13.4 % wt respectively), which indicates that the GO
affects the crystallinity (layer stacking) of the LDH. Therefore, the 2 % wt, was the
percentage of choice for both G and GO to be incorporated in all G/GO-LDH hybrid
samples as will be shown in the following parts. This minimizes the use of G or GO in
the nanocomposite.

Fig 5-7. GO-LDH hybrids prepared with GO: 2 % (a), 6.2 % (b) and 13.4 % w/w (c).
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5.3.2. Determining the optimum solution volume for the G and GO
dispersion for the preparation of the LDH-G and LDH-GO
hybrids:

A- XRD
Figures 5-8 to 5-11 present the XRD patterns of G/GO-LDH hybrids, prepared by coprecipitation using different G/GO concentrations (mg/ml) of a fixed amount of G or GO
(2 % wt), with LDH of metal cations ratio (M2+/ M3+) of 2:1 and 3:1. The values of
calculated d(003), d(110) and interlayer spaces of all samples are summarized in table 5-2.
For samples prepared using LDH of M2+/ M3+ (2:1), neither the change of G nor the GO
concentration has a noticeable effect on the value of d(003), interlayer space, or d(110).
Same findings were observed among samples prepared by LDH of M2+/ M3+ ratio (3:1);
the LDH parameters has not been affected by either G or GO. In addition the change of the
M2+/ M3+ ratio of the LDH is of insignificance as well, but very slight increase of the
interlayer space in case of 2:1 was observed, because of the higher positive charge density
in the brucite-like layers that accommodates more nitrate anions for neutralization, causing
this slight increase [111][112]. When the hybrids were compared to pristine LDH (2:1 and
3:1) controls, the G and GO reflections disappeared and were found to superimpose with
those of the LDHs, because G and GO were incorporated in a small weight percentage
from the total hybrid weight.
All of the previous observations generally indicate that no intercalation of G or GO has
taken place, and the hybrid is rather formed via adsorption on LDH surfaces. Moreover,
the intensities of the peaks, which are related to the crystallinity of the LDH samples are
not affected by the presence of G or GO.
Based on the above, hybrid samples with the lowest concentration of G or GO (0.04
mg/ml) were chosen for drug loading. This has two advantages: it minimizes the effect of
G or GO on the LDH formation, and also ensures minimal possibilities of agglomeration
between G or GO in the hybrid samples.
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Fig 5-8. XRD patterns of G (a), Zn2-Cp (b), Zn2-G.04-Cp (c), Zn2-G.1-Cp (d), Zn2-G.2-Cp (e),
and Zn2-G.4-Cp (f).

Fig 5-9. XRD patterns of GO (g), Zn2-Cp (h), Zn2-GO.04-Cp (i), Zn2-GO.1-Cp (j), Zn2GO.2-Cp (k), and Zn2-GO.4-Cp (l).
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Fig 5-10. XRD patterns of G (a), Zn3-Cp (b), Zn3-G.04-Cp (c), Zn3-G.1-Cp (d), Zn3-G.2-Cp (e),
and Zn3-G.4-Cp (f).

Fig 5-11. XRD patterns of GO (g), Zn3-Cp (h), Zn3-GO.04-Cp (i), Zn3-GO.1-Cp (j), Zn3-GO.2-Cp (k),
and Zn3-GO.4-Cp (l).
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Table 5-2. The calculated d-spacings and interlayer spaces of prepared G/GO-LDH hybrids, with different
concentrations of G and GO (mg/ml) and metal cations ratio of LDH.

Sample

d-spacing
(Å)

Interlayer
space
(Å)

d (003)

d (110)

Zn2-G.04-Cp

8.6

1.54

3.89

Zn2-G.1-Cp

9.0

1.53

Zn2-G.2-Cp

8.8

Zn2-G.4-Cp

Sample

d-spacing
(Å)

Interlayer
space
(Å)

d (003)

d (110)

Zn2-GO.04-Cp

8.8

1.53

4.03

4.29

Zn2-GO.1-Cp

8.7

1.53

3.99

1.54

4.10

Zn2-GO.2-Cp

8.8

1.54

4.03

9.0

1.53

4.23

Zn2-GO.4-Cp

8.8

1.54

4.03

Zn3-G.04-Cp

7.8

1.54

3.03

Zn3-GO.04-Cp

8.7

1.53

4.01

Zn3-G.1-Cp

9.0

1.53

4.26

Zn3-GO.1-Cp

9.0

1.54

4.23

Zn3-G.2-Cp

9.0

1.54

4.26

Zn3-GO.2-Cp

8.9

1.54

4.13

Zn3-G.4-Cp

9.0

1.53

4.23

Zn3-GO.4-Cp

8.9

1.53

4.13

B- FTIR
Figures from 5-12 to 5-15 are FTIR spectra of the prepared G/GO-LDH hybrids. The
characteristic bands of pristine LDH are superimposed on those of G and GO. The
characteristic broad band at around 3400 cm-1 is attributed to the OH group of the brucitelike layers and the adsorbed water molecules as well as the OH groups of GO where
applicable [20][113]. The band at around 1600 cm-1 is due to the H-O-H bending
vibration of the interlayer water molecules. Highly intense nitrate band at around 1384
cm-1, which proves the absence of intercalation of G or GO in the LDH interlayer space.
The vibration bands appearing at lower frequencies (around 400, 600, and 800cm-1) are
assigned to the M-O and M-O-M bonds of the brucite-like layer, which indicates that the
G and GO have no effect on the brucite-like layers [113].

73

Fig 5-12. FTIR spectra of G (a), Zn2-Cp (b) Zn2-G.04-Cp (c), Zn2-G.1-Cp (d), Zn2-G.2-Cp (e),
and Zn2-G.4-Cp (f).

Fig 5-13. FTIR spectra of GO (g), Zn2-Cp (h), Zn2-GO.04-Cp (i), Zn2-GO.1-Cp (j), Zn2-GO.2Cp (k), and Zn2-GO.4-Cp Cp (l).
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Fig 5-14. FTIR spectra of G (a), Zn3-Cp (b), Zn3-G.04-Cp (c) , Zn3-G.1-Cp (d), Zn3-G.2-Cp (e),
and Zn3-G.4-Cp (f).

Fig 5-15. FTIR spectra of GO (g), Zn3-Cp (h), Zn3-GO.04-Cp (i) , Zn3-GO.1-Cp (j), Zn3-GO.2Cp (k), and Zn3-GO.4-Cp (l).
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5.4. Loading of Alendronate sodium
In this section, for each loaded system, the XRD results were analyzed for successful
drug intercalation, followed by their FT-IR spectra to confirm the XRD findings. The
systems were then tested for their loading efficiency, and those showing best intercalation
results are tested for theirs in-vitro drug release behavior.

5.4.1. Co-precipitation samples:
A- XRD
Figures 5-16 and 5-17 show the XRD patterns of samples A-Zn3-Cp, A-Zn3-G-Cp and
A-Zn3-GO-Cp, which are prepared by co-precipitation using M2+/M3+ ratio of 3:1. All of
the three samples showed an obvious shift of the (003) reflection to a lower 2θ value
indicating an expansion in the d-spacing when compared to their corresponding
precursors: Zn3-Cp, Zn3-G.04-Cp, and Zn3-GO.04-Cp respectively, as summarized in
table 5-3.
A-Zn3-Cp, (figure 5-16), showed a huge shift of the (003) reflection to a lower 2θ of
4.8°; corresponding to an expansion of the d(003) from 8.6 Å to 18.3 Å. When
subtracting the brucite-like layer thickness (4.77 Å), the interlayer space is calculated to
be 13.5 Å [110]. The expansion of the interlayer space suggests the successful
intercalation of alendronate sodium. The interlayer gallery (13.5 Å) is greater than the
maximum height of one drug anion (6.1 Å) [115][116], suggesting drug intercalation in a
bi-layered arrangement [55][61][104]. These results are similar to those reported for the
intercalation of Ketoprofen, with the most comparable molecular size value (8.2 Å) in
Mg/Al system, giving an interlayer distance of 17.2 Å, suggesting its intercalation as
slightly tilted bi-layer [60]. In addition, the broadening of the reflections along the XRD
pattern is an indication of decreased crystallinity post drug’s intercalation [61]. The
calculated d value for plane (110) is 1.53 Å, which is almost the same as that of the
precursor (1.52 Å), therefore, the brucite-like layers are not affected by the hosted drug
[61].
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Fig 5-16. XRD patterns of alendronate sodium (a), pristine LDH Zn3-Cp (b), and A-Zn3-Cp (c).

For samples A-Zn3-G-Cp and A-Zn3-GO-Cp (figure 5-17), the reflection at (003) shifted
to lower 2θ values of 4.77° and 4.98°, giving an expansion of the d(003) of 18.5 Å and
17.73 Å respectively when compared to their precursors, 7.8 and 8.7 Å respectively.
Subtracting the brucite-like layer thickness (4.77 Å), the interlayer distances are
calculated as 13.7 Å and 12.9 Å respectively [110]. The reflection peaks of the G or GO
don’t appear, being superimposed by those of the LDH phase [117]. The expansion of the
interlayer spacing can be explained by the successful intercalation of the drug in a bilayered arrangement (12.2 Å). While drug loaded on G or GO surface is probably
adsorbed on the surface of the LDH. The preparation of a drug loaded G/GO-LDH
nanocomposite by co-precipitation was not reported by others in the literature, but rather
the loading of antibacterial benzyl penicillin by ionic exchange using solvent evaporation
process has been reported. Their XRD results for GO-benzyl penicillin-LDH were similar
to that of the benzyl penicillin-LDH, that by turn has shown a bi-layered arrangement of
the drug (11.7 Å), attributed to the interlayer distance of 17.4 Å. The non significant
effect of the GO on the drug-LDH reflection indicated its surface adsorption rather than
intercalation [61].
The presence of G or GO may have prevented the proper stacking of the brucite-like
layers during co-precipitation leading to a decrease in crystallinity, indicated by the
broadening of the XRD reflections, especially that at plane (003) [6][55][61]. This is
indeed more noticeable for sample A-Zn3-G-Cp, probably due to G tending to
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agglomerate by π-π stacking, and thus preventing the layer stacking of the LDH. This is
indicated by the slight increase in the interlayer space for this sample as compared to that
of A-Zn3-GO-Cp [6][118][119].
The calculated d values for plane (110), in both samples are the same as that of their
precursors (1.54 and 1.53 Å respectively), which is an indication that the brucite-like
layers remained unchanged and not affected by the presence of either G or GO [61].

Fig 5-17. XRD patterns of alendronate sodium (a), Zn3-G.04-Cp (b), A-Zn3-G-Cp (c), Zn3-GO.04-Cp (d),
and A-Zn3-GO-Cp (e).

Table 5-3. Comparison between the parameters of the loaded samples prepared by co-precipitation using
metal cations ratio of 3:1 and their controls.

Before drug loading
Sample
precursor

2θ
(at 003
plane)

d-spacing
(Å)
d
(003)

Zn3-Cp
Zn3-G.04Cp
Zn3-GO.04Cp

After drug loading
Interlayer
space
(Å)

Loaded
Sample

2θ
(at 003
plane)

d
(110)

10.3°

8.6

1.52

3.83

11.3°

7.8

1.54

3.00

10.1°

8.7

1.53

4.02
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A-Zn3-Cp
A-Zn3-GCp
A-Zn3GO-Cp

d-spacing
(Å)

Interlayer
space
(Å)

d
(003)

d
(110)

4.8°

18.3

1.53

13.53

4.8°

18.5

1.54

13.70

5.0°

17.7

1.53

12.90

Figure 5-18 and 5-19, show XRD patterns of samples A-Zn2-Cp, A-Zn2-G-Cp and
A-Zn2-GO-Cp, which are prepared by co-precipitation, using a M2+/M3+ ratio of 2:1. The
samples were compared to their corresponding precursors: Zn2-Cp, Zn2-G.04-Cp and
Zn2-GO.04-Cp respectively.
The XRD pattern of A-Zn2-Cp (figure 5-18) shows an obvious collapse of the LDH
layered structure. The very weak reflections at high 2θ values are attributed to the metal
oxides of the disordered brucite like layers [104][111]. It is suggested that the ratio used
for the M2+/M3+ (2:1), is rendering the brucite-like layers more positive than the 3:1 ratio,
and therefore, the LDH structure would need to accommodate more negatively charged
anions to neutralize these charges. However, the large size of the drug molecule cannot fit
in the interlayers, and fails to neutralize the positively charged brucite-like layers and
hinders its proper stacking, and thus resulting in the loss of the of layered structure of
LDH [6][119].

Fig 5-18. XRD patterns of alendronate sodium (a), pristine LDH Zn2-Cp (b), and A-Zn2-Cp (c).

The XRD patterns of A-Zn2-G-Cp and A-Zn2-GO-Cp (figure 5-19), show same XRD
features as previous sample (A-Zn2-Cp), indicating the collapse of the LDH layered
structure. All three samples (A-Zn2-Cp, A-Zn2-G-Cp, and A-Zn2-GO-Cp), show traces
of reflections at high 2θ, that correspond to the metal oxide of the disordered brucitelike layers [104][111].
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Fig 5-19. XRD patterns of alendronate sodium (a), Zn2-G.04-Cp (b), A-Zn2-G-Cp (c), Zn2GO.04-Cp (d), and A-Zn2-GO-Cp (e).

B- FTIR
Figure 5-20 shows the FTIR spectra of A-Zn3-Cp compared to its precursor (Zn3-Cp)
and free alendronate sodium. The loaded system (A-Zn3-Cp) shows the pristine LDH
characteristic broad band at around 3442 cm-1, that is attributed to the OH groups of the
brucite-like layers and the adsorbed water molecules, as well as the OH group in the free
alendronate sodium. This band overlaps with the stretching vibration band of N-H
(primary amine) of the free alendronate sodium, that appears in the range of 3400-3250
cm-1 [56][106][113]. The band at around 1641 cm-1 is due to the H-O-H bending vibration
of the interlayer water molecules of the LDH. The decrease in intensity suggests a
disturbance in the interlayer water molecules. The intensity of the nitrate band at 1383
cm-1 in pristine LDH has noticeably decreased in the loaded sample (A-Zn3-Cp),
indicating the displacement of the nitrate anions by alendronate sodium [113][120].
However, the incomplete disappearance of the band may indicate the presence of some
retained nitrate anions [1]. The free drug shows distinctive bands between 925 and 1238
cm-1, which are attributed to the stretching vibrations of C-O and P=O bonds. In the
loaded sample, these peaks were shifted, and overlapped, giving a broader peak at around
1118 cm-1. This suggests a hydrogen-bond interaction with the brucite-like layers
[121][122]. The peaks appearing in pristine LDH at 576.6 and 971 cm-1, assigned to the
M-O and M-O-M bonds of the LDH [113], are down shifted in the loaded sample from
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their original frequencies (428, 606, 831 cm-1), to 576 and 971 cm-1,suggesting a guesthost interaction between the drug and the OH groups of the brucite-like layers, which is
also supported by their overlap with the 1118 cm-1 band of the loaded drug [113]. This
confirms the successful intercalation of the alendronate sodium into the LDH interlayer,
as has been suggested.

Fig 5-20. FTIR spectra of A-Zn3-Cp (a), Zn3-Cp (b), and alendronate sodium (c).

Figure 5-21 and 5-22 show the FTIR spectra of A-Zn3-G-Cp and A-Zn3-GO-Cp
compared to their corresponding precursors Zn3-G.04-Cp and Zn3-GO.04-Cp
respectively, as well as free alendronate sodium. Both loaded systems have same
interpretation bands’ features as the above sample (A-Zn3-Cp) as follows:






OH broad band at around 3440 cm-1 ( that also corresponds to the COOH of GO in
sample A-Zn3-GO-Cp).
H-O-H bending vibration band at around 1620 cm-1.
Nitrate band at around 1384 cm-1.
C-O and P=O stretching bands of alendronate sodium for sample A-Zn3-G-Cp and
A-Zn3- GO-Cp at 1116 and 1114 cm-1 respectively.
M-O and M-O-M vibration bands at around 600 and 940 cm-1.

The decrease in the nitrate band intensity indicates its displacement with the drug. This
decrease is more noticeable in these two samples (A-Zn3-G-Cp and A-Zn3-GO-Cp) than
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that of A-Zn3-Cp, because the expansion of the interlayer spaces as observed in their
XRD patterns indicates an increased amount of intercalated drug. The intercalation is also
proven by the overlap and the shift of the alendronate sodium band giving a single broad
band, and the down shift of M-O and M-O-M bands [113][121][122].

Fig 5-21. FTIR spectra of A-Zn3-G-Cp (a), Zn3-G.04-Cp (b), and alendronate sodium (c).

Fig 5-22. FTIR spectra of A-Zn3-GO-Cp (a), Zn3-GO.04-Cp (b), and alendronate sodium (c).
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Figure 5-23, shows the FTIR spectra of A-Zn2-Cp compared to its precursor Zn2-Cp and
free alendronate sodium. As mentioned previously, the XRD result for A-Zn2-Zp, has
shown a collapse in the LDH structure, with only traces of reflections corresponding to
the disordered brucite-like layers. Therefore, the FTIR shows the characteristic peaks for
the LDH as discussed previously, which mainly correspond to the brucite-like layers in
addition to other features as follows:






OH vibration broad band at around 3440 cm-1.
H-O-H bending vibration band at 1640 cm-1.
Nitrate band at 1384 cm-1.
C-O and P=O stretching vibration bands of the alendronate sodium appears at
1112 cm-1.
M-O and M-O-M vibration bands at 426 and 580 cm-1.

The nitrate band intensity is noticeable due to failure of intercalation. However, it is of
low intensity than that of the precursor, due to the loss of the nitrate anions neutralizing
the brucite-like layers. In addition, The presence of the characteristic band of the drug,
indicates its presence in the LDH environment. This can possibly indicate the alendronate
sodium adsorption on the surface of the brucite-like layers. Although most of the M-O
and the M-OM bands are still at their original frequencies, one of which is down shifted
and overlapping with that of the drug (1112 cm-1), which could explain the presence of
weak hydrogen bonding between the drug and the brucite-like layers [121][122].

Fig 5-23. FTIR spectra of A-Zn2-Cp (a), Zn2-Cp (b), and alendronate sodium (c).
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Figure 5-24 and 5-25 show the FTIR spectra of A-Zn2-G-Cp and A-Zn2-GO-Cp
respectively, which have the same FTIR features and interpretation as in previous sample
(A-Zn2-Cp), as follows:






OH broad band at around 3440 cm-1.
H-O-H bending vibration band at 1630 cm-1.
Nitrate band at 1380 cm-1.
C-O and P=O stretching bands of the alendronte sodium at around 1110 cm-1.
M-O and M-O-M vibration bands around 570 and 960 cm-1.

The M-O and M-O-M bands in these two samples (A-Zn2-G-Cp and A-Zn2-GO-Cp), are
all down shifted to around 570 and 960 cm-1, compared to previous sample (A-Zn2-Cp),
which indicates the presence of stronger hydrogen bonding of drug loaded on the G or
GO and brucite-like layers.

Fig 5-24. FTIR spectra of A-Zn2-G-Cp (a), Zn2-G.04-Cp (b), and alendronate sodium (c).
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Fig 5-25. FTIR spectra of A-Zn2-GO-Cp (a), Zn2-GO.04-Cp (b), and alendronate sodium (c).

5.4.2. Ion-exchange samples:

A- XRD
Figures 5-26 and 5-27 show the XRD patterns of samples A-Zn3-IE, A-Zn3-G-IE and AZn3-GO-IE, which are prepared by loading the free drug dissolved in an aqueous media
by ion exchange with the dispersed precursor Zn3-Cp, Zn3-G.04-Cp and Zn3-GO.04-Cp
respectively. The parameters are calculated and summarized in table 5-4.
XRD pattern of sample A-Zn3-IE (figure 5-26), shows a huge downshift of 2θ from 10.3°
to 4.74°, to give a d(003) expansion of ≈18.62 Å, and by subtracting the brucite-like layer
thickness (4.77 Å), the calculated interlayer distance is equal to 13.82 Å, suggesting the
intercalation of the drug in a bi-layered arrangement [55][61][104]. The peak at (003) is
broad and of low intensity, indicating disturbance of the layer stacking to some extent
[6][55]. However, the reflections at (006), (012), and (110) suggest that the LDH
structure somehow still keeps its integrity and is not completely distorted. The calculated
d value for the (110) plane is 1.52 Å, which is as same as that of the precursor, indicating
that the brucite-like layers are not affected during ion exchange [61]. These are similar to
findings reported by Ambrogi et al. for the intercalation of diclofenac in Mg/Al LDH by
ion exchange, suggesting their arrangement as bi-layers, which was indicated by the
interlayer distance value compared to the drug molecule height [58]. The d-spacing
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expansion value is also similar to those reported by literature (Michelle Chakraborti
2011), for intercalation of alendronate sodium in Mg/Al LDH giving an interlayer
distance of 12.8 Å [124].

Fig 5-26. XRD patterns of alendronate sodium (a), pristine LDH Zn3-Cp (b), and A-Zn3-IE (c).

The XRD patterns of samples A-Zn3-G-IE and A-Zn3-GO-IE (figure 5-27), show a very
slight shift of the peak at plane (003) to a higher 2θ of 11.79° and 11.2°, corresponding to
d-spacing values of 7.5 and 7.85 Å respectively. When subtracting the brucite-like layer
thickness (4.77 Å), the calculated interlayer gallery heights are 2.73 and 3.09 Å for Zn3G.04-Cp and Zn3-GO.04-Cp respectively [110]. The interlayer gallery height is lower
than the maximum height of one drug molecule (6.1 Å) [114][116]. Moreover, the size of
carbonate is 1.31Å, which excludes the possibility of contamination with dissolved
carbonate [6][102][123]. This therefore seems to indicate that no exchange reaction has
taken place. The slight interlayer compaction could be due to the loss of some nitrate
anions during the high contact with the solution (24 hr). In both samples, the significance
of the reflections at (006), (012), and (110) suggests that the LDH structure still keeps its
integrity and is not completely distorted [1][111]. The calculated d values for the (110)
planes of both samples are 1.54 and 1.534 Å respectively, which indicates that the
brucite-like layers are intact [61]. These findings were different than the previously
mentioned study by Wang et al., reporting the preparation of GO-benzyl penicillin-LDH
nanocomposite by ionic exchange using solvent evaporation process [61]. The
nanocomposite have shown a successful intercalation of the drug in bi-layered
arrangement, and surface adsorption of the GO. This difference is attributed to the
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different preparation techniques used. Where the GO suspension is mixed with that of
benzyl penicillin-LDH and allowed to evaporate under temperature [61]. While in this
paper, the drug is rather mixed with as-prepared G or GO-LDH precursor, and allowed to
stir for long period of time.

Fig 5-27. XRD patterns of alendronate sodium (a), Zn3-G.04-Cp (b), A-Zn3-G-IE (c), Zn3-GO.04-Cp (d),
and A-Zn3-GO-IE (e).

Table 5-4. Comparison between the parameters of the loaded samples prepared by ion-exchange, using
ametal cations ratio of 3:1 and their controls.

Before drug loading
Sample
precursor

2θ
(at 003
plane)

d-spacing
(Å)
d
(003)

Zn3-Cp
Zn3-G.04Cp
Zn3-GO.04Cp

After drug loading
Interlayer
space
(Å)

Loaded
Sample

2θ
(at 003
plane)

d
(110)

10.3°

8.6

1.52

3.83

11.3°

7.8

1.54

3.00

10.1°

8.7

1.53

4.02
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A-Zn3-IE
A-Zn3-GIE
A-Zn3GO-IE

d-spacing
(Å)

Interlayer
space
(Å)

d
(003)

d
(110)

4.7°

18.6

1.52

13.82

11.8°

7.5

1.54

2.73

11.2°

7.8

1.53

3.09

Figures 5-28 and 5-29 show the XRD patterns of samples A-Zn2-IE, A-Zn2-G-IE and AZn2-GO-IE, which are prepared by loading the free drug dissolved in an aqueous media
by ion exchange with the dispersed precursor Zn2-Cp, Zn2-G.04-Cp and Zn2-GO.04-Cp
respectively. The parameters are calculated and summarized in table 5-5.
The XRD pattern for sample A-Zn2-IE (figure 5-28). Shows a shift of the peak at plane
(003) to a lower 2θ of 4.5°, and a d-spacing expansion of 18.5 Å. After subtracting the
brucite-like layer thickness (4.77 Å), it gives an interlayer space of 13.73 Å, suggesting
the intercalation of the drug in a bi-layered arrangement [55][61][104]. The peak at (003)
is broad and of low intensity, indicating disturbance of the layer stacking of the LDH
[6][55]. The calculated d(110) is 1.53 Å, indicating no change in the brucite-like layer
[61].

Fig 5-28. XRD patterns of alendronate sodium (a), pristine LDH Zn2-Cp (b), and A-Zn2-IE (c).

The XRD patterns of samples A-Zn2-G-IE and A-Zn2-GO-IE (figure 5-29), show no
noticeable change of the d-spacing (8.7 and 8.5 Å respectively) compared to their
precursors (8.6 and 8.8 Å respectively). After subtracting the brucite-like layer thickness
(4.77 Å), it gives an interlayer distance of 3.8 and 4 Å respectively, which is equal to the
size of the nitrate anion (4 Å). These findings suggests failure of drug exchange with
nitrate anions. The reflections at (006), (012), and (110) are wide and of low intensity due
to the disturbance in the interlayer anions during exchange [1][111]. The calculated
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d(110) is 1.53 Å, same as that of the precursors indicating no change in the brucite-like
layer [61].

Fig 5-29. XRD patterns of alendronate sodium (a), Zn2-G.04-Cp (b), A-Zn2-G-IE (c), Zn2-GO.04-Cp (d),
and A-Zn2-GO-IE (e).

Table 5-5. Comparison between the parameters of the loaded samples prepared by ion-exchange, using
metal cations ratio of 2:1 and their controls.

Before drug loading
Sample
precursor

2θ
(at 003
plane)

d-spacing
(Å)
d
(003)

Zn2-Cp
Zn2-G.04Cp
Zn2-GO.04Cp

After drug loading
Interlayer
space
(Å)

Loaded
Sample

2θ
(at 003
plane)

d
(110)

9.7°

9.1

1.53

4.30

10.2°

8.6

1.53

3.89

10.0°

8.8

1.53

4.00
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A-Zn2-IE
A-Zn2-GIE
A-Zn2GO-IE

d-spacing
(Å)

Interlayer
space
(Å)

d
(003)

d
(110)

4.5°

18.5

1.54

13.7

10.1°

8.76

1.53

3.99

10.6°

8.50

1.53

3.70

B- FTIR
Figure 5-30, shows the FTIR spectra of A-Zn3-IE being compared to its precursor Zn3Cp and free alendronate sodium. The loaded system (A-Zn3-IE), shows the characteristic
broad band at around 3440 cm-1 of pristine LDH, that is attributed to OH groups of the
brucite-like layers, adsorbed water molecules, and the OH group of the free alendronate
sodium [106][113]. This band overlaps with the stretching vibration band of N-H
(primary amine) of the free alendronate sodium, that appears in the range of 3400-3250
cm-1 [56][106][113]. The nitrate band at 1380 cm-1 of pristine LDH has noticeably
decreased, indicating the displacement of the nitrate anions by alendronate sodium, with
possible presence of some retained nitrate anions [113][120]. The free drug shows
distinctive bands between 925 and 1238 cm-1, which attribute to the stretching vibrations
of C-O and P=O bonds. These bands are shifted and overlapped to give a distinctive
broad band at around 1110 cm-1 in the loaded sample, which suggests a hydrogen bond
interaction with the LDH structure [106][121][122]. The vibration bands appearing at
lower frequencies (428, 606, and 831 cm-1) in the pristine LDH are assigned to the
bending vibrations of the M-O and M-O-M bonds in the brucite-like layer [111]. These
bands in the loaded samples are shifted (580 cm-1 and 966 cm -1), suggesting a guest-host
interaction between the drug and the OH groups of the brucite-like layers, which is also
supported by the overlap of these band with that of the drug (1110 cm-1) [113][121][122].
All of these observations confirm the successful intercalation of the alendronate sodium
into the LDH interlayer space as has been suggested by the XRD results [120].

Fig 5-30. FTIR spectra of A-Zn3-IE (a), Zn3-Cp (b), and alendronate sodium (c).
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Figure 5-31 and 5-32, show the FTIR spectra of samples A-Zn3-G-IE and A-Zn3-GO-IE.
Their XRD results have shown failure of intercalation, but the LDH stayed intact.
Therefore, the LDH’s characteristic bands and other band features appears in the FTIR
pattern as follows:





OH broad band at around 3461cm-1.
Nitrate band at around 1363 cm-1.
C-O and P=O stretching vibrations of alendronate sodium at around 1110 cm-1.
M-O and M-O-M bonds at their original frequencies at around 400, 600 and 800
cm-1.

The nitrate band intensity decreases, but did not completely disappear, which indicates
the presence of nitrate traces in the interlayers [113][120]. The decrease in the intensity
is probably because of the loss of nitrates during the long contact with the solution. The
failure of drug exchange is proven by the presence of the M-O and M-O-M bands at their
original frequencies. However, the presence of the characteristic alendronate sodium
band proves the presence of the drug in the system. The drug’s band is shifted from its
original frequencies and overlapped, giving a single broad band at 1110 cm-1, suggesting
a hydrogen bond interaction [106][121][122]. Therefore, the drug seem to be adsorbed on
the surface of the brucite-like layers rather than intercalated. However, one of the M-O
and M-O-M bands overlaps with the drug’s band at 964 cm-1 appears in sample A-Zn3-GIE, but not in A-Zn3-GO-IE, which indicates that the drug in case of A-Zn3-G-IE favors
hydrogen bonding with the brucite-like layers rather than G, which is not the case with
the A-Zn3-GO-IE, where the drug probably favors the adsorption on the highly
functionalized GO rather than the brucite-like layers.

91

c
b

a

Fig 5-31. FTIR spectra of A-Zn3-G-IE (a), Zn3-G.04-Cp (b), and alendronate sodium (c).

Fig 5-32. FTIR spectra of A-Zn3-GO-IE (a), Zn3-GO.04-Cp (b), and alendronate sodium (c).

Figure 5-33, shows the FTIR spectrum of sample A-Zn2-IE. It has same interpretation
and band features as sample A-Zn3-IE, as follows:





OH broad band at around 3440 cm-1 of pristine LDH.
Nitrate nitrate band at around 1367 cm-1.
C-O and P=O stretching vibrations of alendronate sodium appears at 1114 cm-1.
M-O and M-O-M vibration bands of the brucite-like layer at 568, and 966 cm-1.
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The decrease of the nitrate band, is due to displacement with the drug, but with very
small retained traces. The hydrogen bonding and the guest host interaction between the
drug and the brucite-like layers, are supported by the overlapping and shift of the
alendronate sodium band and the down shift of the M-O and M-O-M bands from their
original frequencies [113][121][122].

Fig 5-33. FTIR spectra of A-Zn2-IE (a), Zn2-Cp (b), and alendronate sodium (c).

Figure 5-34 and 5-35, show the FTIR spectra of samples A-Zn2-G-IE and A-Zn2-GO-IE.
They have same interpretation and band features as in samples A-Zn3-G-Cp and A-Zn3GO-Cp as follows:





OH broad band at around 3440 cm-1 of pristine LDH.
Nitrate band at 1384 cm-1.
C-O and P=O stretching vibrations bonds of alendronate sodium at around 1112
cm-1.
M-O and M-O-M vibration bands at around 426, 600 and 800 cm-1.

The nitrate band intensity is very noticeable, which indicates no displacement of the
nitrate anions. The slight decrease in the band intensity is probably because of the loss of
nitrates during the long contact with the solution as previously mentioned rather than
being exchanged. The failure of drug exchange is proven by the presence of the M-O and
M-O-M bands at their original frequencies. However, the characteristic broad band of
alendronate sodium, indicates its presence in the LDH system, suggested to be adsorbed
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on the surface of the brucite-like layer via hydrogen bonding, supported by the
overlapping and shifting of the drug’s band and the overlap of one of the M-O and M-OM bands with the drug’s band at 935 cm-1 and 962 cm-1 for A-Zn2-G-Cp and A-Zn2-GOCp respectively [106][113][121][122].

Fig 5-34. FTIR spectra of A-Zn2-G-IE (a), Zn2-G.04-Cp (b), and alendronate sodium (c).

Fig 5-35. FTIR spectra of A-Zn2-GO-IE (a), Zn2-GO.04-Cp (b), and alendronate sodium (c).
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5.5. Determination of drug loading and release profile
5.5.1. Drug loading:
The amount of drug loaded was calculated for the successfully loaded samples, and the
particle size was measured for such samples in order to investigate the relationship
between the particle size and the amount of loaded drug. There are some suggested
outcomes that could be obtained from such relationship: the particle size might have an
effect on the surface area available for loading (inversely proportional), it could be an
indication to how the drug is loaded (intercalation or surface adsorption), or show any
particles’ agglomerates. A summary of the loading percentages and particle size values
are shown in table (5-6 and 5-7).
In samples prepared by co-precipitation using M2+/M3+ ratio 3:1 (figure 5-36, blue). The
loaded amount of alendronate sodium in sample A-Zn3-Cp is determined to be 25.36 %
w/w (amount of loaded drug (mg) per 100 mg of the total hybrid), this loaded amount
includes both intercalated drug and that adsorbed on the surface of the brucite-like layers.
While the determined intercalated and adsorbed amounts in A-Zn3-G-Cp and A-Zn3-GOCp are 36% and 36.6 % w/w respectively. The G/GO-LDH hybrid samples have shown
an increase in the percentage loaded, due to the increase of the surface available for drug
adsorption provided by the G or GO. Therefore, for the co-precipitated samples, the
effect of G and GO on the drug loading was noticeable. However, the size differences
between the three samples 656.1, 765.2 and 610.0 nm respectively (table 5-6) are limited,
which indicates that loading via intercalation is predominant.
As for samples prepared by co-precipitation using M2+/M3+ ratio 2:1 (figure 5-36,
orange): A-Zn2-Cp, A-Zn2-G-Cp and Zn2-GO-Cp, have shown low percentages of
loaded drug: 15.26%, 12.28%, and 16.4 % w/w respectively. These low loading
percentages are due to the collapse of the LDH structure, leading to no intercalation of
the drug. Loaded drug amounts are believed to be mostly surface adsorbed on the
exfoliated brucite-like layers, and/or on G and GO. The size difference between that of
A-Zn2-Cp and A-Zn2-GO-Cp is minimal (386.4 and 336.9 nm respectively), but that of
A-Zn2-G-Cp (1273.4 nm) is noticeably larger. This might be due to G agglomerating by
π-π stacking, forming large sized particles; without necessarily being accompanied by
adsorption of the drug on the G surface, because these agglomerate hinders the drug to
reach the surface of the G or LDH.
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As an overall findings, the hybrid samples prepared by LDH of M2+/M3+ ratio 3:1(A-Zn3Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp), have higher loading percentages compared to
those prepared by 2:1 ratio (A-Zn2-Cp, A-Zn2-G-Cp and A-Zn2-GO-Cp), with a further
increase in the presence of G or GO.

Table 5-6. The drug loaded amounts and particle sizes of samples prepared by co-precipitation using
M2+/M3+ ratios 2:1 and 3:1 respectively.

Loading

Size

(% w/w)

(nm)

Sample

A-Zn2-Cp

15.3

386.4 ± 85

A-Zn2-G-Cp

16.4

1273.4± 261

A-Zn2-GO-Cp

12.4

336.9± 3

A-Zn3-Cp

25.4

656.1± 16

A-Zn3-G-Cp

36.0

765.2± 43

A-Zn3-GO-Cp

36.6

610.0± 16
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Fig 5-36. A plot of the percentages of the drug loaded (% w/w) versus particle sizes (nm), to compare
between the loading percentages, particle sizes and loading-size relationship, among samples
prepared by same M2+/M3+ ratio, 3:1 (blue) or 2:1 (orange), and between both ratios.

As for the ion-exchange samples A-Zn3-IE (figure 5-37, green) and A-Zn2-IE (figure 537, red), which are prepared using LDH of M2+/M3+ ratio 3:1 and 2:1 respectively, the
loaded percentages are 50.5% and 51 % w/w respectively. Both samples almost have the
same loading values, in spite of their size difference (380.9 and 853.0 nm respectively),
which is very noticeable, suggesting that loading is primarily via intercalation and the
size difference is rather due to particles’ agglomeration. The loading percentage is high
compared to their equivalents in the co-precipitation samples, indicating that the nitrate
groups have been largely exchanged during the long contact time with the drug.
As for samples A-Zn3-G-IE (figure 5-37, green) and A-Zn2-G-IE (figure 5-37, red), the
loading percentages are 22.5% and 57.3 % w/w respectively. As discussed previously in
the XRD results, these two samples have shown loss in the ordered arrangement of the
brucite-like layers, therefore the drug loading is believed to primarily be by surface
adsorption, with higher loading percentage in sample A-Zn2-G-IE, because the LDH of
M2+/M3+ ratio of 2:1 possesses more positive charges, and hence attracting more drug
anions onto its surface. This explains the difference in drug loaded amount in spite of the
comparable particle size (568.8 and 562.8 nm respectively).
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Finally, samples A-Zn3-GO-IE and A-Zn2-GO-IE show almost the same sizes, 299.7 and
290.5 nm respectively and loading percentages: 24 and 25.9 % w/w with slight increase
in the latter because of the high positive charges (M2+/M3+ ratio is 2:1). The relatively low
loading % in both is attributed to the presence of GO, which may be contributing to the
neutralization of charges of the brucite-like layers limiting drug adsorption on the LDH
surface.
As an overall findings, the samples prepared using LDH of M2+/M3+ ratio 2:1, and their
corresponding in 3:1 samples, have relatively comparable loading percentages, except AZn2-G-IE, which has high loading percentage than A-Zn3-G-IE, due to the high charge
density as previously discussed. They all have comparable sizes as well except A-Zn2-IE,
which has bigger size than A-Zn3-IE, which could be due to agglomeration caused by the
high charge density. However, hybrids with GO (A-Zn2-GO-IE, A-Zn3-GO-IE) have
shown the lowest loaded amount, due to GO competing to neutralize the brucite-like
layers as previously discussed.

Table 5-7. The drug loaded amounts and particle sizes of samples prepared by ion-exchange using M2+/M3+
ratios 2:1 and 3:1 respectively.

Loading

Size

(% w/w)

(nm)

Sample

A-Zn2-IE

51.0

853.0± 19

A-Zn2-G-IE

57.3

562.8± 24

A-Zn2-GO-IE

25.9

290.5± 3

A-Zn3-IE

50.5

380.9± 1

A-Zn3-G-IE

22.4

568.8± 32

A-Zn3-GO-IE

24.0

299.7± 0
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Fig 5-37. A plot of the percentages of the drug loaded (% w/w) versus particle sizes (nm), to compare
between the loading percentages, particle sizes and loading-size relationship, among samples
prepared by same M2+/M3+ ratio, 3:1 (green) or 2:1 (red), and between both ratios.

System A-Zn2-IE, A-Zn2-G-IE and A-Zn3-IE, are with the highest loaded drug amounts
(57.3, 51 and 50.5 mg respectively), which are equivalent to 1.3, 1.04 and 1 mg of
alendronate sodium in each mg of the system (drug-LDH, drug-G-LDH and drug-LDH
respectively), either adsorbed on the LDH surface or intercalated. These amounts of drug
loaded are higher than that reported in the previously mentioned literature reported by
Chakraborti (2011) [124], where the alendronate sodium intercalated in Mg/Al LDH
system was 0.6 mg/mg LDH [124].

5.5.2. Drug release profile:
Based on the previously discussed XRD and FTIR results, the release profile of the
samples that have shown successful loading via intercalation was studied in water for a
period of 24 hours according to the USP for alendronate sodium. While the samples that
have shown drug loading via surface adsorption were excluded from this study, as would
give a burst release rather than sustained.
Figure 5-38 plots the percentage of drug released from the systems prepared by coprecipitation using M2+/M3+ ratio 3:1: A-Zn3-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp versus
time in hours. The three systems show a highly sustained release profile over 24 hours,
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giving a slight increase at the end with a total release of 3.5%, 4.2% and 2.9%, from AZn3-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp hybrid systems respectively. This is attributed
to the strong attachment of the positively charged brucite-like layers to the intercalated
drug guest. The sample with the lowest total release percentage is A-Zn3-GO-Cp is the,
because GO has a highl functionalized platform that attracts the drug onto its surface
through hydrogen bonding, slightly hindering the release of the drug when compared to
the other two samples. Followed by Sample A-Zn3-Cp with a slightly higher total release
percentage, because it has less charge density, where only the brucite-like layer is the
surface attracting the drug, facilitating the release. And finally sample A-Zn3-G-Cp, with
the highest total release percentage, because some of the drug is attached to the surface
of the brucite-like layer, and others are weakly attached to the surface of G
(unfunctinalized), therefore, the drug is easily released.
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Fig 5-38. Release profile of A-Zn3-Cp (blue), A-Zn3-G-Cp (red) and A-Zn3-GO-Cp
(green).

Figure 5-39 shows the release profile of the samples prepared by ion exchange: A-Zn2-IE
and A-Zn3-IE, of metal cations ratio 3:1 and 2:1 respectively. The release profile shows a
sustained release over 24 hours, giving a total release percentage of 2.1% and 2.5%. The
total release percentage of sample A-Zn3-IE is slightly higher, attributed to the fact that
the LDH with M2+/M3+ ratio of 3:1 has lower positive charge density than that of sample
A-Zn2-IE (M2+/M3+, 2:1), and therefore, is more likely to lose the hosted drug easily. But
in case of A-Zn2-IE, the drug is more attached to the brucite-like layer, hindering it
release.
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Fig 5-39. Release profile of A-Zn2-IE (blue), and A-Zn3-IE (red).

Table 5-8. Amounst and percentages of drug released from 100 mg of hybrid system at 24 hr.

Time interval
(hr)

Amount released from 100 mg
of hybrid sample at 24 hr
(mg)
0.90

% Released from 100 mg
of hybrid sample at 24 hr

A-Zn3-G-Cp

1.52

4.2±0.034

A-Zn3-GO-Cp

1.08

2.9±0.003

A-Zn2-IE

1.07

2.1±0.002

A-Zn3-IE

1.28

2.5±0.013

A-Zn3-Cp

3.5± 0.009

Table 5-8 presents a summary of the amounts and percentages of drug released at 24 hr
from 100 mg of the hybrid system. These results have been compared to literature
reported by Chakraborti [124]. The literature showed burst release of ≈45 % over the 6
hour, while that of the systems in this research work, the release over the 6 hours is
ranging between 1.7-2.9 %, which continue with a sustained behavior for 24 hrs with
maximum drug release ranging between 2.1-4.2 %. As for the one reported in literature
had shown a sustained release over 6 days with approximate release of 80 %.
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5.6. Summary of the work and results
The work is summarized in the following points:


G was oxidized to GO sheets by Hummers method and characterized by XRD,
FTIR and SEM.



Zn-Al-NO3 LDH controls of M2+/M3+ ratios 2:1 and 3:1 were prepared for
comparison with the loaded corresponding samples.



Different amounts of G and GO were incorporated with the LDHs by coprecipitation, and the crystallinity of the resulting nanocomposites investigated.
The 2 % w/w had the best LDH crystallinity, and therefore was chosen as the
amount of G and GO to be incorporated.



The masses of G and GO corresponding to a content of 2 % w/w in the
nanocomposite, were dispersed in water of different volumes to result in
suspensions of different concentrations. This was for the purpose of investigating
whether the volume of water in which the G and GO were dispersed had any
effect on the composition and crystallinity of the final LDH-G and LDH-GO
nanocomposites. Different dispersion concentrations gave comparable results for
crystallinity. Therefore, the lowest dispersion concentration was chosen (highest
volume of water) to ensure better G and GO dispersion.



The formed nanocomposites were loaded with alendronate sodium by two
methods: co-precipitation and ion exchange. They were then characterized by
XRD and FTIR, where some have showed loading via intercalation and
adsorption.



Only samples with successful intercalation were tested for their release profile.
These exhibited sustained release over 24 hours.



The prepared samples and a summary of their results are summarized in the
following table (5-9).
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Table 5-9. All prepared samples and their results, with respect to the following aspects: drug loading mechanism, loaded amount (% w/w), and the total drug
released at 24 hr (% of total load).

Zn-Al-NO3 (M2+/M3+, 2:1)
Loaded by co-precipitation
Samples

A-Zn2-Cp
A-Zn2-G-Cp
A-Zn2-GO-Cp

Loading method

Loaded by ion-exchange

Loaded
amount
(%
w/w)

Total drug
released
over 24 hr
(% of total
load)

15.3

Drug not
intercalated

Primarily via Surface adsorption on
LDH layers
Primarily via Surface adsorption on
LDH layers and G
Primarily via Surface adsorption on
LDH layers and GO

16.4
12.4

Samples

A-Zn2-IE

Drug not
intercalated
Drug not
intercalated

A-Zn2-G-IE
A-Zn2-GO-IE

Loading method

Loaded
amount
(%
w/w)

Primarily via intercalation in
bi-layer
arrangement
and
surface adsorption on LDH
Primarily
via
surface
adsorption on LDH and G
Primarily
via
surface
adsorption on LDH and GO

51.0
57.3
25.9

Total drug
released
over 24 hr
(% of total
load)
2.1
Drug not
intercalated
Drug not
intercalated

Zn-Al-NO3 ( M2+/M3+, 3:1)
Loaded by co-precipitation
Samples

A-Zn3-Cp
A-Zn3-G-Cp
A-Zn3-GO-Cp

Loading method

Primarily via intercalation in a
bi-layer arrangement and surface
adsorption on LDH
Primarily via intercalation in a
bi-layer arrangement and surface
adsorption LDH and G
Primarily via intercalation in a
bi-layer arrangement and surface
adsorption LDH and GO

Loaded by ion-exchange

Loaded
amount
(%w/w)

Total drug
released
over 24 hr
(% of total
load)

Samples

A-Zn3-IE
25.4

3.5

36.0

4.2

36.6

2.9

A-Zn3-G-IE
A-Zn3-GO-IE
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Loading method

Primarily via intercalation in
a bi-layer arrangement and
surface adsorption on LDH
Primarily
via
surface
adsorption on LDH and G
Primarily
via
surface
adsorption on LDH and GO

Loaded
amount
(%w/w)

Total released
Over 24 hr
(% of total
load)

50.5

2.5

22.4

Drug not
intercalated

24.0

Drug not
intercalated

Table 5-10. Schematic presentation of the drug loading mechanism in the prepared loaded samples, where each component is represented as follows:
LDH(

Sample

Loading
mechanism

A-Zn3-Cp

Primarily by
intercalation in a
bi-layer arrangement
and surface
adsorption on LDH.

A-Zn3-G-Cp,

Primarily by
intercalation in a
bi-layer arrangement
and surface
adsorption LDH and
G.

A-Zn3-Go-Cp

Primarily by
intercalation in a
bi-layer arrangement
and surface
adsorption LDH and
GO.

), Interlayer nitrate anions (

), drug anions (

), G (

), and GO(

Co-precipitation prepared samples
Schematic presentation
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).

A-Zn2-Cp

Primarily by surface
adsorption on LDH
layers

A-Zn2-G-Cp

Primarily by surface
adsorption on LDH
layers and G

A-Zn2-GO-Cp

Primarily by surface
adsorption on LDH
layers and GO
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Ion-Exchange prepared samples
A-Zn2-IE, and
A-Zn3-IE

Primarily by
intercalation in bilayer arrangement
and surface
adsorption on LDH

Primarily by surface
A-Zn2-G-IE,
and A-Zn3-G-IE adsorption on LDH
and G

A-Zn2-GO-IE,
and A-Zn3-GOIE

Primarily by surface
adsorption on LDH
and GO
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6. Conclusion and Future work
6.1. Conclusion
Nanocomposites of G/GO-Zn-Al LDH were prepared, with 2% w/w of G and GO
(prepared by modified Hummers method) incorporated with two different M2+/M3+ ratios
of LDH (2:1 and 3:1), and their use as potential drug delivery systems was tested. The
samples were tested for the loading and release of alendronate sodium, which is a nBP
drug, typically with low bioavailability (< 1%), and gastrointestinal adverse effects.
The nanocomposites, as well as the blank LDH samples, were loaded with alendronate
sodium with two methods: co-precipitation and ion-exchange, and they were then
characterized by XRD and FTIR. The samples that showed successful intercalation of the
drug in bi-layered arrangement are : co-precipitation samples prepared using M2+/M3+ of
3:1 (A-Zn3-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp), and ion exchange samples with either
M2+/M3+ of 2:1 or 3:1, with no G or GO (A-Zn2-IE and A-Zn3-IE). Their drug loading
amounts were found to be 25.4, 36.0, 36.6, 51.0, and 50.5 % w/w respectively. The G
and GO had a noticeable effect on the amount of drug loaded in the co-precipitation
samples (51 and 50.0 % respectively). The release of the drug from these systems were
sustained showing almost a plateau over 24 hours, with minimum amounts released, and
a total release percentages after 24 hr ranging from 2.1% to 4.2 % which are equivalent to
1.07 and 1.5 mg of the drug respectively, released from 100 mg of the system.
For samples that did not show successful intercalation (A-Zn2-Cp, A-Zn2-G-Cp, A-Zn2GO-Cp, A-Zn2-G-IE, A-Zn2-GO-IE, A-Zn3-G-IE, and A-Zn3-GO-IE), drug loading was
by surface adsorption on the LDH brucite-like layers and G/GO. Their corresponding
drug loading amounts are 15.3, 16.4, 12.4, 57.3, 25.9, 22.4, and 24 % w/w respectively.
Samples prepared by co-precipitation using M2+/M3+ of 2:1 (A-Zn2-Cp, A-Zn2-G-Cp,
and A-Zn2-GO-Cp) were with the lowest loaded amount of the drug, because of the
collapse of the LDH layered structure. While samples prepared by ion-exchange,
incorporating G/GO (A-Zn3-G-IE, A-Zn3-GO-IE, A-Zn2-G-IE and A-Zn2-GO-IE),
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showed the highest loading, because of the long contact of the hybrid with the drug
solution allowing more drug to be adsorbed on the surface.
Findings show that two systems are meeting the criteria of high drug loading and
sustained release behavior. The systems are A-Zn3-G-Cp and A-Zn3-GO-Cp, with loaded
drug amounts of 36 and 36.5 % w/w and sustained release over 24 hrs with total amount
released 1.52 and 1.08 mg, which are the highest among samples.

6.2. Future work
Future work would focus on the following aspect:


Molecular simulation, to predict the arrangement of the drug molecules in the
LDH interlayers, as well as those adsorbed on the surface.



To perform a mucus adsorption and a cellular uptake studies to investigate the
permeability of the hybrid through the GIT mucus membrane, and its uptake by
the bone cells.



Toxicity test of the hybrid to identify limit of toxicity for oral intake of the
required dose.
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Calibration curve of Alendronate sodium in simulated gastric fluid for the loading
determination test.
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